0001838359--12-31 2025 Q2 http://fasb.org/us-gaap/2025#PrimeRateMember P10Y P10Y P5Y P20D P30D P5Y P20D P30D P18D P12D 0.50 false 0001838359 us-gaap:WarrantMember 2025-04-01 2025-06-30 0001838359 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001838359 us-gaap:WarrantMember 2024-04-01 2024-06-30 0001838359 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001838359 rgti:PrivateWarrantMember us-gaap:MeasurementInputSharePriceMember 2025-06-30 0001838359 rgti:PrivateWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-06-30 0001838359 rgti:PrivateWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2025-06-30 0001838359 rgti:PrivateWarrantMember us-gaap:MeasurementInputExpectedTermMember 2025-06-30 0001838359 rgti:PrivateWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-06-30 0001838359 rgti:PrivateWarrantMember us-gaap:MeasurementInputExercisePriceMember 2025-06-30 0001838359 rgti:PrivateWarrantMember us-gaap:MeasurementInputSharePriceMember 2024-12-31 0001838359 rgti:PrivateWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001838359 rgti:PrivateWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001838359 rgti:PrivateWarrantMember us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001838359 rgti:PrivateWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0001838359 rgti:PrivateWarrantMember us-gaap:MeasurementInputExercisePriceMember 2024-12-31 0001838359 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2025-04-01 2025-06-30 0001838359 us-gaap:AdditionalPaidInCapitalMember rgti:AtMarketOfferingAgreementMember 2025-04-01 2025-06-30 0001838359 us-gaap:PrivatePlacementMember 2025-04-01 2025-06-30 0001838359 rgti:AtMarketOfferingAgreementMember 2025-04-01 2025-06-30 0001838359 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2025-01-01 2025-06-30 0001838359 us-gaap:AdditionalPaidInCapitalMember rgti:AtMarketOfferingAgreementMember 2025-01-01 2025-06-30 0001838359 us-gaap:PrivatePlacementMember 2025-01-01 2025-06-30 0001838359 rgti:AtMarketOfferingAgreementMember 2025-01-01 2025-06-30 0001838359 us-gaap:AdditionalPaidInCapitalMember rgti:AtMarketOfferingAgreementMember 2024-04-01 2024-06-30 0001838359 us-gaap:AdditionalPaidInCapitalMember rgti:CommonStockPurchaseAgreementMember 2024-01-01 2024-06-30 0001838359 us-gaap:AdditionalPaidInCapitalMember rgti:AtMarketOfferingAgreementMember 2024-01-01 2024-06-30 0001838359 us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-12-31 0001838359 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001838359 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001838359 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-04-01 2025-06-30 0001838359 us-gaap:CommonStockMember rgti:AtMarketOfferingAgreementMember 2025-04-01 2025-06-30 0001838359 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-01-01 2025-06-30 0001838359 us-gaap:CommonStockMember rgti:AtMarketOfferingAgreementMember 2025-01-01 2025-06-30 0001838359 us-gaap:CommonStockMember rgti:AtMarketOfferingAgreementMember 2024-04-01 2024-06-30 0001838359 us-gaap:CommonStockMember rgti:CommonStockPurchaseAgreementMember 2024-01-01 2024-06-30 0001838359 us-gaap:CommonStockMember rgti:AtMarketOfferingAgreementMember 2024-01-01 2024-06-30 0001838359 rgti:CommonStockPurchaseAgreementMember 2024-01-01 2024-06-30 0001838359 rgti:PostConversionMember us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-12-31 0001838359 2022-03-02 2022-03-02 0001838359 us-gaap:RetainedEarningsMember 2025-06-30 0001838359 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001838359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001838359 us-gaap:RetainedEarningsMember 2025-03-31 0001838359 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001838359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001838359 2025-03-31 0001838359 us-gaap:RetainedEarningsMember 2024-12-31 0001838359 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001838359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001838359 us-gaap:RetainedEarningsMember 2024-06-30 0001838359 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001838359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001838359 us-gaap:RetainedEarningsMember 2024-03-31 0001838359 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001838359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001838359 2024-03-31 0001838359 us-gaap:RetainedEarningsMember 2023-12-31 0001838359 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001838359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001838359 us-gaap:CommonStockMember 2025-06-30 0001838359 us-gaap:CommonStockMember 2025-03-31 0001838359 us-gaap:CommonStockMember 2024-12-31 0001838359 us-gaap:CommonStockMember 2024-06-30 0001838359 us-gaap:CommonStockMember 2024-03-31 0001838359 us-gaap:CommonStockMember 2023-12-31 0001838359 rgti:SharePriceEqualOrExceedsAboveDollarTwoPerShareMember us-gaap:RestrictedStockUnitsRSUMember 2025-06-30 0001838359 rgti:SharePriceEqualOrExceedsAboveDollarFourPerShareMember us-gaap:RestrictedStockUnitsRSUMember 2025-06-30 0001838359 rgti:SharePriceEqualOrExceedsAboveDollarFourPerShareMember us-gaap:RestrictedStockUnitsRSUMember 2025-01-31 0001838359 rgti:SharePriceEqualOrExceedsAboveDollarTwoPerShareMember us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001838359 us-gaap:RestrictedStockUnitsRSUMember rgti:MarketBasedVestingRestrictedStockUnitsMember 2023-01-01 2023-12-31 0001838359 us-gaap:RestrictedStockMember 2025-01-01 2025-06-30 0001838359 us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0001838359 2024-01-01 2024-12-31 0001838359 rgti:MarketBasedVestingAwardMember 2022-01-01 2022-12-31 0001838359 us-gaap:RestrictedStockUnitsRSUMember rgti:TimeBasedVestingRestrictedStockUnitsMember 2025-01-01 2025-06-30 0001838359 us-gaap:RestrictedStockUnitsRSUMember rgti:TimeBasedVestingRestrictedStockUnitsMember 2024-01-01 2024-06-30 0001838359 rgti:SharePriceEqualOrExceedsAboveDollarTwoPerShareMember us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001838359 rgti:SharePriceEqualOrExceedsAboveDollarFourPerShareMember us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001838359 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember rgti:TimeBasedVestingRestrictedStockUnitsMember 2025-01-01 2025-06-30 0001838359 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember rgti:TimeBasedVestingRestrictedStockUnitsMember 2025-01-01 2025-06-30 0001838359 srt:MinimumMember rgti:TimeBasedVestingAwardMember 2025-01-01 2025-06-30 0001838359 srt:MaximumMember rgti:TimeBasedVestingAwardMember 2025-01-01 2025-06-30 0001838359 us-gaap:LeaseholdImprovementsMember rgti:SingleReportableSegmentMember 2025-04-01 2025-06-30 0001838359 rgti:QuantumComputingFridgesMember rgti:SingleReportableSegmentMember 2025-04-01 2025-06-30 0001838359 rgti:ProcessEquipmentMember rgti:SingleReportableSegmentMember 2025-04-01 2025-06-30 0001838359 rgti:ItHardwareMember rgti:SingleReportableSegmentMember 2025-04-01 2025-06-30 0001838359 rgti:ConstructionInProgressAndOtherAssetMember rgti:SingleReportableSegmentMember 2025-04-01 2025-06-30 0001838359 us-gaap:LeaseholdImprovementsMember rgti:SingleReportableSegmentMember 2025-01-01 2025-06-30 0001838359 rgti:QuantumComputingFridgesMember rgti:SingleReportableSegmentMember 2025-01-01 2025-06-30 0001838359 rgti:ProcessEquipmentMember rgti:SingleReportableSegmentMember 2025-01-01 2025-06-30 0001838359 rgti:ItHardwareMember rgti:SingleReportableSegmentMember 2025-01-01 2025-06-30 0001838359 rgti:ConstructionInProgressAndOtherAssetMember rgti:SingleReportableSegmentMember 2025-01-01 2025-06-30 0001838359 us-gaap:LeaseholdImprovementsMember rgti:SingleReportableSegmentMember 2024-04-01 2024-06-30 0001838359 rgti:QuantumComputingFridgesMember rgti:SingleReportableSegmentMember 2024-04-01 2024-06-30 0001838359 rgti:ItHardwareMember rgti:SingleReportableSegmentMember 2024-04-01 2024-06-30 0001838359 rgti:ConstructionInProgressAndOtherAssetMember rgti:SingleReportableSegmentMember 2024-04-01 2024-06-30 0001838359 us-gaap:LeaseholdImprovementsMember rgti:SingleReportableSegmentMember 2024-01-01 2024-06-30 0001838359 rgti:QuantumComputingFridgesMember rgti:SingleReportableSegmentMember 2024-01-01 2024-06-30 0001838359 rgti:ProcessEquipmentMember rgti:SingleReportableSegmentMember 2024-01-01 2024-06-30 0001838359 rgti:ItHardwareMember rgti:SingleReportableSegmentMember 2024-01-01 2024-06-30 0001838359 rgti:ConstructionInProgressAndOtherAssetMember rgti:SingleReportableSegmentMember 2024-01-01 2024-06-30 0001838359 us-gaap:SalesRevenueNetMember 2025-01-01 2025-06-30 0001838359 us-gaap:AccountsReceivableMember 2025-01-01 2025-06-30 0001838359 2025-02-27 2025-02-27 0001838359 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2025-04-01 2025-06-30 0001838359 srt:AsiaMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2025-04-01 2025-06-30 0001838359 country:US us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2025-04-01 2025-06-30 0001838359 us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2025-04-01 2025-06-30 0001838359 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2025-01-01 2025-06-30 0001838359 srt:AsiaMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2025-01-01 2025-06-30 0001838359 country:US us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2025-01-01 2025-06-30 0001838359 us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2025-01-01 2025-06-30 0001838359 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2024-04-01 2024-06-30 0001838359 srt:AsiaMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2024-04-01 2024-06-30 0001838359 country:US us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2024-04-01 2024-06-30 0001838359 us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2024-04-01 2024-06-30 0001838359 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2024-01-01 2024-06-30 0001838359 srt:AsiaMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2024-01-01 2024-06-30 0001838359 country:US us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2024-01-01 2024-06-30 0001838359 us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember rgti:SingleReportableSegmentMember 2024-01-01 2024-06-30 0001838359 2026-06-30 2025-06-30 0001838359 us-gaap:TransferredOverTimeMember 2025-04-01 2025-06-30 0001838359 rgti:CollaborativeResearchAndOtherProfessionalServicesMember 2025-04-01 2025-06-30 0001838359 rgti:AccessToQuantumComputingSystemsMember 2025-04-01 2025-06-30 0001838359 us-gaap:TransferredOverTimeMember 2025-01-01 2025-06-30 0001838359 rgti:CollaborativeResearchAndOtherProfessionalServicesMember 2025-01-01 2025-06-30 0001838359 rgti:AccessToQuantumComputingSystemsMember 2025-01-01 2025-06-30 0001838359 us-gaap:TransferredOverTimeMember 2024-04-01 2024-06-30 0001838359 us-gaap:TransferredAtPointInTimeMember 2024-04-01 2024-06-30 0001838359 rgti:CollaborativeResearchAndOtherProfessionalServicesMember 2024-04-01 2024-06-30 0001838359 rgti:AccessToQuantumComputingSystemsMember 2024-04-01 2024-06-30 0001838359 us-gaap:TransferredOverTimeMember 2024-01-01 2024-06-30 0001838359 us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-06-30 0001838359 rgti:CollaborativeResearchAndOtherProfessionalServicesMember 2024-01-01 2024-06-30 0001838359 rgti:AccessToQuantumComputingSystemsMember 2024-01-01 2024-06-30 0001838359 rgti:LoanAndSecurityAgreementMember 2024-12-09 2024-12-09 0001838359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001838359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-06-30 0001838359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001838359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001838359 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001838359 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001838359 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001838359 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001838359 rgti:QuantaComputerCollaborationAgreementMemberMember 2025-02-27 2025-02-27 0001838359 rgti:PublicWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeMember 2025-06-30 0001838359 rgti:PrivateWarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeMember 2025-06-30 0001838359 us-gaap:FairValueInputsLevel3Member 2025-06-30 0001838359 rgti:PublicWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeMember 2024-12-31 0001838359 rgti:PrivateWarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeMember 2024-12-31 0001838359 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001838359 us-gaap:FairValueInputsLevel2Member rgti:UsTreasurySecuritiesShortTermMember 2025-06-30 0001838359 us-gaap:FairValueInputsLevel2Member rgti:UsTreasurySecuritiesLongTermMember 2025-06-30 0001838359 us-gaap:FairValueInputsLevel1Member rgti:UsTreasurySecuritiesShortTermMember 2025-06-30 0001838359 us-gaap:FairValueInputsLevel2Member 2025-06-30 0001838359 us-gaap:FairValueInputsLevel1Member 2025-06-30 0001838359 us-gaap:FairValueInputsLevel2Member rgti:UsTreasurySecuritiesShortTermMember 2024-12-31 0001838359 us-gaap:FairValueInputsLevel2Member rgti:UsTreasurySecuritiesLongTermMember 2024-12-31 0001838359 us-gaap:FairValueInputsLevel2Member 2024-12-31 0001838359 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001838359 rgti:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member rgti:DerivativeWarrantLiabilitiesMember 2025-06-30 0001838359 rgti:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member rgti:DerivativeWarrantLiabilitiesMember 2024-12-31 0001838359 rgti:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member rgti:DerivativeWarrantLiabilitiesMember 2024-06-30 0001838359 us-gaap:FairValueInputsLevel3Member rgti:ContingentEarnOutLiabilityMember 2024-06-30 0001838359 rgti:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member rgti:DerivativeWarrantLiabilitiesMember 2023-12-31 0001838359 us-gaap:FairValueInputsLevel3Member rgti:ContingentEarnOutLiabilityMember 2023-12-31 0001838359 us-gaap:FairValueInputsLevel3Member rgti:ContingentEarnOutLiabilityMember 2025-04-01 2025-06-30 0001838359 us-gaap:FairValueInputsLevel3Member rgti:ContingentEarnOutLiabilityMember 2025-01-01 2025-03-31 0001838359 rgti:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member rgti:DerivativeWarrantLiabilitiesMember 2024-04-01 2024-06-30 0001838359 us-gaap:FairValueInputsLevel3Member rgti:ContingentEarnOutLiabilityMember 2024-04-01 2024-06-30 0001838359 rgti:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member rgti:DerivativeWarrantLiabilitiesMember 2024-01-01 2024-03-31 0001838359 us-gaap:FairValueInputsLevel3Member rgti:ContingentEarnOutLiabilityMember 2024-01-01 2024-03-31 0001838359 rgti:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member rgti:DerivativeWarrantLiabilitiesMember 2025-04-01 2025-06-30 0001838359 rgti:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member rgti:DerivativeWarrantLiabilitiesMember 2025-01-01 2025-03-31 0001838359 rgti:PrivateWarrantMember 2025-01-01 2025-06-30 0001838359 rgti:PrivateWarrantsMember 2025-04-01 2025-06-30 0001838359 rgti:PrivateWarrantsMember 2025-01-01 2025-06-30 0001838359 rgti:PublicWarrantsMember 2024-04-01 2024-06-30 0001838359 rgti:PrivateWarrantsMember 2024-04-01 2024-06-30 0001838359 rgti:PublicWarrantsMember 2024-01-01 2024-06-30 0001838359 rgti:PrivateWarrantsMember 2024-01-01 2024-06-30 0001838359 srt:MaximumMember 2025-06-30 0001838359 rgti:LoanAndSecurityAgreementMember 2025-01-01 2025-06-30 0001838359 srt:MinimumMember rgti:LoanAndSecurityAgreementMember 2025-06-30 0001838359 rgti:LoanAndSecurityAgreementMember 2024-06-30 0001838359 rgti:LoanAndSecurityAgreementMember 2024-12-09 0001838359 rgti:LoanAndSecurityAgreementMember 2024-06-21 0001838359 rgti:LoanAndSecurityAgreementMember 2022-01-31 0001838359 rgti:LoanAndSecurityAgreementMember 2021-11-30 0001838359 rgti:LoanAndSecurityAgreementMember 2021-05-31 0001838359 rgti:LoanAndSecurityAgreementMember 2021-03-31 0001838359 srt:MinimumMember rgti:LoanAndSecurityAgreementMember 2025-01-01 2025-06-30 0001838359 rgti:GovernmentEntitiesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0001838359 rgti:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0001838359 rgti:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0001838359 rgti:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0001838359 rgti:GovernmentEntitiesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0001838359 rgti:CustomerFMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2025-01-01 2025-06-30 0001838359 rgti:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0001838359 rgti:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0001838359 rgti:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2025-01-01 2025-06-30 0001838359 rgti:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0001838359 rgti:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2025-01-01 2025-06-30 0001838359 rgti:GovernmentEntitiesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001838359 rgti:CustomerFMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001838359 rgti:CustomerEMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001838359 rgti:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001838359 rgti:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001838359 rgti:CustomerEMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-01-01 2024-12-31 0001838359 rgti:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-01-01 2024-12-31 0001838359 rgti:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-01-01 2024-12-31 0001838359 rgti:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-01-01 2024-12-31 0001838359 rgti:GovernmentEntitiesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001838359 rgti:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001838359 rgti:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001838359 rgti:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001838359 rgti:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001838359 us-gaap:CommonClassAMember rgti:CommonStockPurchaseAgreementMember 2022-08-11 0001838359 rgti:CommonStockPurchaseAgreementMember 2022-08-11 0001838359 2022-03-02 0001838359 us-gaap:RestrictedStockUnitsRSUMember 2025-06-30 0001838359 us-gaap:EmployeeStockOptionMember 2025-06-30 0001838359 rgti:TwoThousandTwentyTwoEquityIncentivePlanMember 2025-06-30 0001838359 rgti:CommonStockWarrantsMember 2025-06-30 0001838359 rgti:VestedCustomerWarrantsMember 2025-06-30 0001838359 rgti:UnvestedCustomerWarrantsMember 2025-06-30 0001838359 rgti:SeriesCRedeemableConvertiblePreferredStockMember 2025-06-30 0001838359 rgti:PrivateWarrantsMember 2025-06-30 0001838359 rgti:VestedCustomerWarrantsMember 2024-12-31 0001838359 rgti:UnvestedCustomerWarrantsMember 2024-12-31 0001838359 rgti:SeriesCRedeemableConvertiblePreferredStockMember 2024-12-31 0001838359 rgti:PublicWarrantsMember 2024-12-31 0001838359 rgti:PrivateWarrantsMember 2024-12-31 0001838359 srt:MinimumMember rgti:PublicWarrantsMember 2025-06-30 0001838359 srt:MaximumMember rgti:PublicWarrantsMember 2025-06-30 0001838359 us-gaap:WarrantMember 2025-06-30 0001838359 rgti:PublicWarrantsMember 2025-06-30 0001838359 us-gaap:WarrantMember 2024-06-30 0001838359 rgti:PublicWarrantsMember 2022-03-22 0001838359 rgti:PrivatePlacementWarrantsMember 2022-03-22 0001838359 rgti:SeriesCRedeemableConvertiblePreferredStockMember rgti:WarrantsToPurchaseClassACommonStockMember 2020-12-31 0001838359 us-gaap:SeriesCPreferredStockMember 2020-12-31 0001838359 rgti:CustomerWarrantsMember us-gaap:CommonClassAMember 2020-02-29 0001838359 2024-06-30 0001838359 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2025-06-30 0001838359 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2024-12-31 0001838359 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2024-12-31 0001838359 us-gaap:MeasurementInputSharePriceMember 2025-06-30 0001838359 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-06-30 0001838359 us-gaap:MeasurementInputPriceVolatilityMember 2025-06-30 0001838359 us-gaap:MeasurementInputExpectedTermMember 2025-06-30 0001838359 rgti:MeasurementInputSimulatedTradingDaysMember 2025-06-30 0001838359 us-gaap:MeasurementInputSharePriceMember 2024-12-31 0001838359 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001838359 us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001838359 us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001838359 rgti:MeasurementInputSimulatedTradingDaysMember 2024-12-31 0001838359 us-gaap:MoneyMarketFundsMember 2025-06-30 0001838359 us-gaap:CashEquivalentsMember 2025-06-30 0001838359 us-gaap:USTreasurySecuritiesMember 2024-12-31 0001838359 us-gaap:MoneyMarketFundsMember 2024-12-31 0001838359 us-gaap:CashEquivalentsMember 2024-12-31 0001838359 rgti:UsTreasurySecuritiesShortTermMember 2025-06-30 0001838359 rgti:AvailableForSaleSecurityShortTermMember 2025-06-30 0001838359 rgti:AvailableForSaleSecurityLongTermMember 2025-06-30 0001838359 rgti:UsTreasurySecuritiesShortTermMember 2024-12-31 0001838359 rgti:UsTreasurySecuritiesLongTermMember 2024-12-31 0001838359 rgti:AvailableForSaleSecurityShortTermMember 2024-12-31 0001838359 rgti:AvailableForSaleSecurityLongTermMember 2024-12-31 0001838359 rgti:SponsorVestingSharesMember 2025-04-01 2025-06-30 0001838359 us-gaap:WarrantMember us-gaap:CommonClassAMember 2025-01-01 2025-06-30 0001838359 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonClassAMember 2025-01-01 2025-06-30 0001838359 us-gaap:EmployeeStockOptionMember us-gaap:CommonClassAMember 2025-01-01 2025-06-30 0001838359 us-gaap:CommonClassAMember 2025-01-01 2025-06-30 0001838359 rgti:UnvestedCustomerWarrantsMember 2025-01-01 2025-06-30 0001838359 rgti:SponsorVestingSharesMember 2025-01-01 2025-06-30 0001838359 rgti:SponsorVestingSharesMember 2024-04-01 2024-06-30 0001838359 us-gaap:WarrantMember us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0001838359 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0001838359 us-gaap:EmployeeStockOptionMember us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0001838359 us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0001838359 rgti:UnvestedCustomerWarrantsMember 2024-01-01 2024-06-30 0001838359 rgti:SponsorVestingSharesMember 2024-01-01 2024-06-30 0001838359 rgti:LoanAndSecurityAgreementMember 2024-04-01 2024-06-30 0001838359 rgti:LoanAndSecurityAgreementMember 2024-01-01 2024-06-30 0001838359 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-04-01 2025-06-30 0001838359 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2025-06-30 0001838359 us-gaap:ResearchAndDevelopmentExpenseMember 2025-04-01 2025-06-30 0001838359 us-gaap:EmployeeStockOptionMember 2025-04-01 2025-06-30 0001838359 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-01-01 2025-06-30 0001838359 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-06-30 0001838359 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0001838359 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0001838359 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001838359 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001838359 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0001838359 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0001838359 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001838359 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001838359 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001838359 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001838359 2023-12-31 0001838359 rgti:SupernovaAcquisitionMember rgti:SponsorAgreementMember us-gaap:SubsequentEventMember 2025-08-11 2025-08-11 0001838359 rgti:SupernovaAcquisitionMember rgti:SponsorAgreementMember us-gaap:SubsequentEventMember 2025-08-08 2025-08-08 0001838359 rgti:SupernovaAcquisitionMember rgti:SponsorAgreementMember 2022-03-02 2022-03-02 0001838359 rgti:SupernovaAcquisitionMember rgti:SponsorAgreementMember rgti:TrancheTwoMember 2022-03-02 0001838359 rgti:SupernovaAcquisitionMember rgti:SponsorAgreementMember rgti:TrancheOneMember 2022-03-02 0001838359 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001838359 rgti:QuantaComputerIncMember rgti:QuantaComputerCollaborationAgreementMemberMember 2025-02-27 2025-02-27 0001838359 rgti:OpenMarketSalesAgreementMember 2025-06-30 0001838359 rgti:CommonStockPurchaseAgreementMember 2025-06-30 0001838359 rgti:AtMarketOfferingAgreementMember 2025-06-30 0001838359 srt:MaximumMember rgti:PublicWarrantsMember 2025-04-01 2025-06-30 0001838359 rgti:OpenMarketSalesAgreementMember 2025-04-01 2025-06-30 0001838359 rgti:AtMarketOfferingAgreementMember 2024-04-01 2024-06-30 0001838359 rgti:AtMarketOfferingAgreementMember 2024-01-01 2024-06-30 0001838359 rgti:TwoThousandTwentyTwoEquityIncentivePlanMember 2025-01-01 2025-06-30 0001838359 rgti:CommonStockPurchaseAgreementMember 2022-08-11 2022-08-11 0001838359 2025-01-02 2025-01-02 0001838359 rgti:SupernovaAcquisitionMember rgti:SponsorAgreementMember srt:MinimumMember us-gaap:SubsequentEventMember 2025-08-11 2025-08-11 0001838359 rgti:SupernovaAcquisitionMember rgti:SponsorAgreementMember srt:MaximumMember us-gaap:SubsequentEventMember 2025-08-11 2025-08-11 0001838359 rgti:SupernovaAcquisitionMember rgti:SponsorAgreementMember srt:MinimumMember us-gaap:SubsequentEventMember 2025-08-08 2025-08-08 0001838359 rgti:SupernovaAcquisitionMember rgti:SponsorAgreementMember srt:MaximumMember us-gaap:SubsequentEventMember 2025-08-08 2025-08-08 0001838359 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001838359 rgti:SupernovaAcquisitionMember rgti:SponsorAgreementMember rgti:TrancheTwoMember 2022-03-02 2022-03-02 0001838359 rgti:SupernovaAcquisitionMember rgti:SponsorAgreementMember rgti:TrancheOneMember 2022-03-02 2022-03-02 0001838359 2024-04-01 2024-06-30 0001838359 rgti:OpenMarketSalesAgreementMember 2025-05-29 0001838359 rgti:AtMarketOfferingAgreementMember 2024-03-15 0001838359 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001838359 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001838359 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001838359 2025-04-01 2025-06-30 0001838359 rgti:TwoThousandTwentyTwoEquityIncentivePlanMember 2025-01-01 0001838359 rgti:DerivativeWarrantLiabilitiesMember 2025-04-01 2025-06-30 0001838359 rgti:DerivativeWarrantLiabilitiesMember 2025-01-01 2025-06-30 0001838359 rgti:CustomerWarrantsMember us-gaap:CommonClassAMember 2025-01-01 2025-06-30 0001838359 rgti:CustomerWarrantsMember us-gaap:CommonClassAMember 2024-01-01 2024-12-31 0001838359 rgti:UsTreasurySecuritiesLongTermMember 2025-06-30 0001838359 rgti:LoanAndSecurityAgreementMember 2025-06-30 0001838359 rgti:SingleReportableSegmentMember 2025-04-01 2025-06-30 0001838359 rgti:SingleReportableSegmentMember 2025-01-01 2025-06-30 0001838359 rgti:SingleReportableSegmentMember 2024-04-01 2024-06-30 0001838359 rgti:SingleReportableSegmentMember 2024-01-01 2024-06-30 0001838359 us-gaap:FairValueInputsLevel3Member rgti:ContingentEarnOutLiabilityMember 2025-06-30 0001838359 2025-06-30 0001838359 us-gaap:FairValueInputsLevel3Member rgti:ContingentEarnOutLiabilityMember 2024-12-31 0001838359 2024-12-31 0001838359 rgti:QuantaComputerCollaborationAgreementMemberMember 2025-02-27 0001838359 srt:MinimumMember rgti:CustomerWarrantsMember us-gaap:CommonClassAMember 2020-02-01 2020-02-29 0001838359 srt:MaximumMember rgti:CustomerWarrantsMember us-gaap:CommonClassAMember 2020-02-01 2020-02-29 0001838359 rgti:SeriesCRedeemableConvertiblePreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-12-31 0001838359 rgti:SeriesCRedeemableConvertiblePreferredStockMember 2025-04-01 2025-06-30 0001838359 rgti:PublicWarrantsMember 2025-04-01 2025-06-30 0001838359 rgti:SeriesCRedeemableConvertiblePreferredStockMember 2025-01-01 2025-06-30 0001838359 rgti:PublicWarrantsMember 2025-01-01 2025-06-30 0001838359 rgti:RedemptionOfWarrantsWhenPricePerShareOfCommonStockEqualsOrExceeds18.00Member rgti:PublicWarrantsMember 2025-06-30 0001838359 rgti:RedemptionOfWarrantsWhenPricePerShareOfCommonStockEqualsOrExceeds10.00Member rgti:PublicWarrantsMember 2025-06-30 0001838359 rgti:CustomerWarrantsMember us-gaap:CommonClassAMember 2025-06-30 0001838359 2025-02-06 2025-02-06 0001838359 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001838359 2024-01-01 2024-06-30 0001838359 rgti:GailSanfordMember rgti:RestrictedStockUnitsTradingPlanMember 2025-06-30 0001838359 rgti:GailSanfordMember rgti:CommonStockTradingPlanMember 2025-06-30 0001838359 rgti:ThomasIannottiMember 2025-06-30 0001838359 rgti:ThomasIannottiMember 2025-04-01 2025-06-30 0001838359 rgti:GailSanfordMember 2025-04-01 2025-06-30 0001838359 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001838359 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001838359 2025-08-08 0001838359 2025-01-01 2025-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure rgti:security rgti:D rgti:Y

Table of Contents

x

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

​

FORM 10-Q

​

​

☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the quarterly period ended June 30, 2025

or

​

☐ | TRANSITION PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT

​

For the transition period from to

​

Commission File Number (001-40140)

​

,

RIGETTI COMPUTING, INC.

(Exact name of registrant as specified in its charter)

​

​

​ | ​
Delaware | 88-0950636
(State or other jurisdiction of | (I.R.S. Employer
incorporation or organization) | Identification No.)
​ | ​
775 Heinz Avenue | ​
Berkeley California | 94710
(Address of principal executive offices) | (Zip Code)

​

(510) 210-5550

(Registrant’s telephone number, including area code)

​

​

Securities registered pursuant to Section 12(b) of the Act:

​

​ | ​ | ​ | ​ | ​
Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
​ | ​ | ​ | ​ | ​
Common Stock, $0.0001 par value per share | ​ | RGTI | ​ | The Nasdaq Capital Market
Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share | ​ | RGTIW | ​ | The Nasdaq Capital Market

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ Yes ☐ No

​

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

​ | ​ | ​ | ​
Large Accelerated Filer | ☐ | Accelerated Filer | ☐
Non-Accelerated Filer | ☑ | Smaller Reporting Company | ☑
​ | ​ | Emerging Growth Company | ☑

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☑ No

​

As of August 8, 2025, there were 324,165,170 shares of the registrant’s Common Stock issued and outstanding.

​

​

​

​

Table of Contents

TABLE OF CONTENTS

​

​ | ​ | ​
​ | ​ | Page
Cautionary Note Regarding Forward-looking Statements | 2
​ | ​ | ​
PART I — FINANCIAL INFORMATION | 4
​ | ​ | ​
Item 1. | Financial Statements (Unaudited) | 4
​ | Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 | 4
​ | Condensed Consolidated Statements of Operations for the Three and Six Months ended June 30, 2025 and 2024 | 5
​ | Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months ended June 30, 2025 and 2024 | 6
​ | Condensed Consolidated Statements of Cash Flows for the Six Months ended June 30, 2025 and 2024 | 7
​ | Notes to Condensed Consolidated Financial Statements | 8
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 27
Item 3. | Quantitative and Qualitative Disclosures About Market Risks | 35
Item 4. | Controls and Procedures | 35
​ | ​ | ​
PART II — OTHER INFORMATION | 36
​ | ​ | ​
Item 1. | Legal Proceedings | 36
Item 1A. | Risk Factors | 36
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 36
Item 3. | Defaults Upon Senior Securities | 36
Item 4. | Mine Safety Disclosures | 36
Item 5. | Other Information | 37
Item 6. | Exhibits | 38
​ | Signatures | 40

​

​

​

​

1

Table of Contents

Cautionary Note Regarding Forward-looking Statements

Unless the context requires otherwise, references in this report to “Rigetti”, the “Company”, “we”, “us”, and “our” refer to Rigetti Computing, Inc. and its consolidated subsidiaries.

​

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. We have based these forward-looking statements on our current expectations and projections about future events. Any statements that refer to projections, forecasts or other characterizations of future events or circumstances are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “goal,” “objective,” “design,” “seek,” “target,” “should,” “could,” “will,” “would” or the negative of such terms or other similar expressions.

​

These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Most of such risks and uncertainties are difficult to predict and many are beyond our control. Discussion of the risks and uncertainties material to our business can be found under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, as updated under “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q.

​

Given such risks and uncertainties, you should not place undue reliance on these forward-looking statements. In addition, our goals and objectives are aspirational and are not guarantees or promises that such goals and objectives will be met. Should one or more of the risks or uncertainties described in this Quarterly Report on Form 10-Q or our Annual Report on Form 10-K for the year ended December 31, 2024 materialize, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements.

​

Also, these forward-looking statements represent our plans, objectives, estimates, expectations, assumptions, and intentions only as of the date of this filing. Except as otherwise required by applicable law, we disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q.

​

You should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results, levels of activity and performance as well as other events and circumstances may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

​

Forward-looking statements in this Quarterly Report on Form 10-Q may include, for example, statements about:

​

| ● | our ability to achieve milestones, and/or technological advancements, including with respect to executing on our technology roadmap, including the expectation of releasing a 100+ qubit chiplet-based system with a 99.5% median two-qubit gate fidelity before the end of 2025, and developing practical applications,

​

| ● | the potential of quantum computing and estimated market size and market growth including with respect to our long-term business strategies for sales of quantum computers and quantum computing as a service (“Quantum Computing as a Service,” or “QCaaS”),

​

| ● | our ability and timeline to monetize our investments in quantum computing, if at all,

​

| ● | the success of our partnerships and collaborations, including the recent Collaboration Agreement with Quanta Computer, Inc. (“Quanta”),

​

| ● | unfavorable conditions in our industry, the global economy or global supply chain (including any supply chain impacts from future and ongoing military conflicts and wars around the world and sanctions related thereto and trade protections and tariffs), levels of future economic activity, inflation, interest rates and financial and credit market fluctuations,

​

| ● | macroeconomic conditions, including global economic and geopolitical conditions, disruptions to and volatility and uncertainty in the credit and financial markets, uncertainty in levels of future economic activity, inflation and interest rates,

​

​

2

Table of Contents

​

​

| ● | our ability to accelerate our development of multiple generations of quantum processors,

​

| ● | customer concentration and the risk that a significant portion of our revenue currently depends on contracts with the public sector,

​

| ● | the outcome of any legal proceedings that have or may be instituted against us or others,

​

| ● | our ability to execute on our business strategy, including monetization of our products,

​

| ● | our financial performance, growth rate and market opportunity,

​

| ● | our ability to grow and manage growth profitably, maintain relationships with customers and suppliers and retain our management and key employees,

​

| ● | costs related to operating as a public company, including the additional costs associated with the pending loss of our emerging growth company (“EGC”) and smaller reporting company (“SRC”) status under the current rules of the Securities and Exchange Commission (the “SEC”),

​

| ● | the time and attention necessary with respect to our increased disclosure and compliance obligations associated with the pending loss of our EGC and SRC status under the current rules of the SEC.

​

| ● | our ability to maintain effective internal controls over financial reporting,

​

| ● | changes in applicable laws or regulations, including international trade policies and tax legislation,

​

| ● | the possibility that we may be adversely affected by other economic, business, or competitive factors,

​

| ● | the evolution of the markets in which we compete,

​

| ● | our ability to implement our strategic initiatives, expansion plans and continue to innovate our existing products and services,

​

| ● | the sufficiency of our cash resources and our ability to raise additional capital when needed and on attractive terms,

​

| ● | our success in retaining or recruiting, or changes required in, our officers, key employees or directors,

​

| ● | our estimates regarding expenses, profitability, future revenue, capital requirements and needs for additional financing, and

​

| ● | our ability or decisions to expand or maintain our existing customer base.

​

​

​

​

​

3

Table of Contents

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

RIGETTI COMPUTING, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except number of shares and par value)

(unaudited)

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, | ​ | December 31,
​ |  | 2025 |  | 2024
Assets |  |  |  |  |  |
Current assets: |  |  |  |  |  |
Cash and cash equivalents | ​ | $ | 57,183 | ​ | $ | 67,674
Available-for-sale investments - short-term | ​ | ​ | 368,556 | ​ | ​ | 124,420
Accounts receivable | ​ | ​ | 1,753 | ​ | ​ | 2,427
Prepaid expenses | ​ | ​ | 3,056 | ​ | ​ | 3,156
Other current assets | ​ | ​ | 3,031 | ​ | ​ | 9,081
Total current assets | ​ | ​ | 433,579 | ​ | ​ | 206,758
Available-for-sale investments - long-term | ​ | ​ | 145,903 | ​ | ​ | 25,068
Property and equipment, net | ​ | ​ | 48,869 | ​ | ​ | 44,643
Operating lease right-of-use assets | ​ | ​ | 7,217 | ​ | ​ | 7,993
Other assets | ​ | ​ | 1,122 | ​ | ​ | 325
Total assets | ​ | $ | 636,690 | ​ | $ | 284,787
​ | ​ | ​ | ​ | ​ | ​ | ​
Liabilities and Stockholders' Equity | ​ | ​ |  | ​ | ​ |
Current liabilities: | ​ | ​ |  | ​ | ​ |
Accounts payable | ​ | $ | 2,159 | ​ | $ | 1,590
Accrued expenses and other current liabilities | ​ | ​ | 5,955 | ​ | ​ | 8,005
Current portion of deferred revenue | ​ | ​ | 118 | ​ | ​ | 113
Current portion of operating lease liabilities | ​ | ​ | 2,198 | ​ | ​ | 2,159
Total current liabilities | ​ | ​ | 10,430 | ​ | ​ | 11,867
Deferred revenue, less current portion | ​ | ​ | 698 | ​ | ​ | 698
Operating lease liabilities, less current portion | ​ | ​ | 5,812 | ​ | ​ | 6,641
Derivative warrant liabilities | ​ | ​ | 60,116 | ​ | ​ | 93,095
Earn-out liabilities | ​ | ​ | 6,371 | ​ | ​ | 45,897
Total liabilities | ​ | ​ | 83,427 | ​ | ​ | 158,198
Commitments and contingencies (Note 16) | ​ | ​ |  | ​ | ​ |
Stockholders’ equity: | ​ | ​ | ​ | ​ | ​ | ​
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, none outstanding | ​ | ​ | — | ​ | ​ | —
Common stock, par value $0.0001 per share, 1,000,000,000 shares authorized, 323,762,157 shares issued and outstanding at June 30, 2025 and 283,546,871 shares issued and outstanding at December 31, 2024 | ​ | ​ | 32 | ​ | ​ | 29
Additional paid-in capital | ​ | ​ | 1,104,880 | ​ | ​ | 681,202
Accumulated other comprehensive income | ​ | ​ | 133 | ​ | ​ | 105
Accumulated deficit | ​ | ​ | (551,782) | ​ | ​ | (554,747)
Total stockholders’ equity | ​ | ​ | 553,263 | ​ | ​ | 126,589
Total liabilities and stockholders’ equity | ​ | $ | 636,690 | ​ | $ | 284,787

​

See accompanying notes to condensed consolidated financial statements.

​

4

Table of Contents

RIGETTI COMPUTING, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
​ |  | Three Months Ended June 30, |  | Six Months Ended June 30,
​ |  | 2025 |  | 2024 |  | 2025 |  | 2024
Revenue | ​ | $ | 1,801 | ​ | $ | 3,086 | ​ | $ | 3,273 | ​ | $ | 6,138
Cost of revenue | ​ | ​ | 1,235 | ​ | ​ | 1,096 | ​ | ​ | 2,265 | ​ | ​ | 2,648
Total gross profit | ​ | ​ | 566 | ​ | ​ | 1,990 | ​ | ​ | 1,008 | ​ | ​ | 3,490
Operating expenses: | ​ | ​ |  | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ |
Research and development | ​ | ​ | 13,522 | ​ | ​ | 11,870 | ​ | ​ | 28,977 | ​ | ​ | 23,341
Selling, general and administrative | ​ | ​ | 6,926 | ​ | ​ | 6,205 | ​ | ​ | 13,545 | ​ | ​ | 12,819
Total operating expenses | ​ | ​ | 20,448 | ​ | ​ | 18,075 | ​ | ​ | 42,522 | ​ | ​ | 36,160
Loss from operations | ​ | ​ | (19,882) | ​ | ​ | (16,085) | ​ | ​ | (41,514) | ​ | ​ | (32,670)
Other income (expense), net | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
Interest expense | ​ | ​ | — | ​ | ​ | (969) | ​ | ​ | — | ​ | ​ | (2,076)
Interest income | ​ | ​ | 3,042 | ​ | ​ | 1,218 | ​ | ​ | 5,194 | ​ | ​ | 2,341
Change in fair value of derivative warrant liabilities | ​ | ​ | (20,557) | ​ | ​ | 2,100 | ​ | ​ | 32,705 | ​ | ​ | (483)
Change in fair value of earn-out liabilities | ​ | ​ | (2,257) | ​ | ​ | 1,315 | ​ | ​ | 6,580 | ​ | ​ | (306)
Total other income (expense), net | ​ | ​ | (19,772) | ​ | ​ | 3,664 | ​ | ​ | 44,479 | ​ | ​ | (524)
Net income (loss) before provision for income taxes | ​ | ​ | (39,654) | ​ | ​ | (12,421) | ​ | ​ | 2,965 | ​ | ​ | (33,194)
Provision for income taxes | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Net income (loss) | ​ | $ | (39,654) | ​ | $ | (12,421) | ​ | $ | 2,965 | ​ | $ | (33,194)
Net loss available to common stockholders used in diluted earnings per share | ​ | $ | (39,654) | ​ | $ | (12,421) | ​ | $ | (1,398) | ​ | $ | (33,194)
Net income (loss) per share attributable to common stockholders – basic | ​ | $ | (0.13) | ​ | $ | (0.07) | ​ | $ | 0.01 | ​ | $ | (0.21)
Net loss per share attributable to common stockholders – diluted | ​ | $ | (0.13) | ​ | $ | (0.07) | ​ | $ | 0.00 | ​ | $ | (0.21)
Weighted average shares used to compute net income (loss) per share attributable to common stockholders – basic and diluted | ​ | ​ | 298,254 | ​ | ​ | 171,903 | ​ | ​ | 291,514 | ​ | ​ | 161,705

​

See accompanying notes to condensed consolidated financial statements.

​

5

Table of Contents

RIGETTI COMPUTING, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands)

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  |  | ​ | ​ | ​ | ​ |  |  | ​ | ​ | ​ | ​
​ |  | Three Months Ended June 30, |  | Six Months Ended June 30,
​ |  | 2025 |  | 2024 |  | 2025 |  | 2024
Net income (loss) | ​ | $ | (39,654) | ​ | $ | (12,421) | ​ | $ | 2,965 | ​ | $ | (33,194)
Other comprehensive income (loss): | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
Foreign currency translation adjustments | ​ | ​ | 156 | ​ | ​ | (17) | ​ | ​ | (29) | ​ | ​ | (105)
Unrealized gain (loss) on available-for-sale debt securities | ​ | ​ | 65 | ​ | ​ | 2 | ​ | ​ | 57 | ​ | ​ | (16)
Total other comprehensive income (loss) before income taxes | ​ | ​ | 221 | ​ | ​ | (15) | ​ | ​ | 28 | ​ | ​ | (121)
Income taxes | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Total other comprehensive income (loss) after income taxes | ​ | ​ | 221 | ​ | ​ | (15) | ​ | ​ | 28 | ​ | ​ | (121)
Total comprehensive income (loss) | ​ | $ | (39,433) | ​ | $ | (12,436) | ​ | $ | 2,993 | ​ | $ | (33,315)

​

See accompanying notes to condensed consolidated financial statements.

​

6

Table of Contents

RIGETTI COMPUTING INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  |  | ​ | ​ | ​ | ​
​ |  | Six Months Ended June 30,
​ |  | 2025 |  | 2024
Cash flows from operating activities: | ​ | ​ |  |  |  |
Net income (loss) | ​ | $ | 2,965 | ​ | $ | (33,194)
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ​ | ​ | ​ | ​ | ​ | ​
Depreciation and amortization | ​ | ​ | 3,723 | ​ | ​ | 3,334
Stock-based compensation | ​ | ​ | 7,728 | ​ | ​ | 6,278
Change in fair value of earn-out liabilities | ​ | ​ | (6,580) | ​ | ​ | 306
Change in fair value of derivative warrant liabilities | ​ | ​ | (32,705) | ​ | ​ | 483
Accretion of available-for-sale securities | ​ | ​ | (3,396) | ​ | ​ | (1,776)
Amortization of debt issuance costs, commitment fees and accretion of final payment fees | ​ | ​ | — | ​ | ​ | 547
Non-cash lease expense | ​ | ​ | 776 | ​ | ​ | 784
Changes in operating assets and liabilities: | ​ | ​ | ​ | ​ | ​ | ​
Accounts receivable | ​ | ​ | 674 | ​ | ​ | (203)
Prepaid expenses, other current assets and other assets | ​ | ​ | (836) | ​ | ​ | (1,021)
Deferred revenue | ​ | ​ | 5 | ​ | ​ | 493
Accounts payable | ​ | ​ | 618 | ​ | ​ | (1,085)
Accrued expenses and operating lease liabilities | ​ | ​ | (2,792) | ​ | ​ | (1,602)
Net cash used in operating activities | ​ | ​ | (29,820) | ​ | ​ | (26,656)
Cash flows from investing activities: | ​ | ​ |  | ​ | ​ |
Purchases of property and equipment | ​ | ​ | (8,214) | ​ | ​ | (7,538)
Purchases of available-for-sale securities | ​ | ​ | (438,518) | ​ | ​ | (75,995)
Maturities of available-for-sale securities | ​ | ​ | 77,000 | ​ | ​ | 76,500
Net cash used in investing activities | ​ | ​ | (369,732) | ​ | ​ | (7,033)
Cash flows from financing activities: | ​ | ​ |  | ​ | ​ |
Payments of principal of notes payable | ​ | ​ | — | ​ | ​ | (6,199)
Proceeds from sale of common stock through Common Stock Purchase Agreement | ​ | ​ | — | ​ | ​ | 12,838
Proceeds from sale of common stock through At-The-Market (ATM) Offerings | ​ | ​ | 346,719 | ​ | ​ | 26,833
Proceeds from sale of common stock from Quanta private placement transaction | ​ | ​ | 35,000 | ​ | ​ | —
Payments of offering costs | ​ | ​ | (798) | ​ | ​ | (447)
Net proceeds from tax withholdings on sell-to-cover equity award transactions | ​ | ​ | 6,272 | ​ | ​ | —
Proceeds from issuance of common stock upon exercise of stock options | ​ | ​ | 1,443 | ​ | ​ | 68
Proceeds from issuance of common stock upon exercise of warrants | ​ | ​ | 459 | ​ | ​ | —
Net cash provided by financing activities | ​ | ​ | 389,095 | ​ | ​ | 33,093
Effects of exchange rate changes on cash and cash equivalents | ​ | ​ | (34) | ​ | ​ | (112)
Net decrease in cash and cash equivalents | ​ | ​ | (10,491) | ​ | ​ | (708)
Cash and cash equivalents – beginning of period | ​ | ​ | 67,674 | ​ | ​ | 21,392
Cash and cash equivalents – end of period | ​ | $ | 57,183 | ​ | $ | 20,684
Supplemental disclosures of other cash flow information: | ​ | ​ |  | ​ | ​ |
Cash paid for interest | ​ | $ | — | ​ | $ | 1,504
Non-cash investing and financing activities: | ​ | ​ | ​ | ​ | ​ | ​
Capitalization of deferred costs to equity upon share issuance | ​ | ​ | — | ​ | ​ | 132
Purchases of property and equipment recorded in accounts payable | ​ | ​ | 417 | ​ | ​ | 739
Purchases of property and equipment recorded in accrued expenses | ​ | ​ | 11 | ​ | ​ | 849
Reclassification of earn-out liabilities to additional paid-in capital for vesting of Promote Sponsor Vesting Shares | ​ | ​ | 32,946 | ​ | ​ | —
Reclassification of derivative liabilities to additional paid-in capital due to exercise of Public Warrants | ​ | ​ | 274 | ​ | ​ | —
Purchases of offering costs in accounts payable | ​ | ​ | 90 | ​ | ​ | 29
Unrealized gain/(loss) on short term investments | ​ | ​ | 57 | ​ | ​ | (16)

​

See accompanying notes to condensed consolidated financial statements.

​

​

7

Table of Contents

RIGETTI COMPUTING INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

​

(1) | Description of Business

​

Rigetti Computing, Inc. and its subsidiaries (collectively, the “Company” or “Rigetti”), builds quantum computers and the superconducting quantum processors that power them. The Company markets a 9-qubit quantum processing unit (“QPU”) under the Novera™ QPU trade name. Through the Company’s Quantum Computing as a Service (“QCaaS”) platform, the Company’s machines can be integrated into any public, private or hybrid cloud.

​

The Company is located and headquartered in Berkeley, California. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia and British Columbia, Canada. The Company’s revenue is derived primarily from operations in the United States and the United Kingdom.

​

(2) Summary of Significant Accounting Policies

​

Basis of Presentation

​

On March 2, 2022 (the “Closing Date”), a merger transaction between Rigetti Holdings, Inc. (“Legacy Rigetti”) and Supernova Partners Acquisition Company II, Ltd. (“SNII”) was completed (the “Business Combination”). In connection with the closing of the Business Combination, the Company changed its name to Rigetti Computing, Inc. and all of SNII Class A ordinary shares and SNII Class B ordinary shares automatically converted into shares of common stock, par value $0.0001, of the Company (the “Common Stock”) on a one-for-one basis. Certain warrants held by SNII became warrants to purchase shares of Common Stock, each entitling the holder to purchase one share of Common Stock at an exercise price of $11.50 per share, that trade on the Nasdaq Capital Market (the “Public Warrants”), while certain other warrants held by SNII became private placement warrants, each entitling the holder to purchase one share of Common Stock at an exercise price of $11.50 per share (the “Private Warrants”). The Company’s Common Stock and Public Warrants trade on the Nasdaq Capital Market under the ticker symbols “RGTI” and “RGTIW,” respectively. The Company determined that Legacy Rigetti was the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in Accounting Standards Codification (ASC) 805, Business Combination.

​

Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Legacy Rigetti issuing stock for the net assets of SNII, accompanied by a recapitalization. The primary asset acquired from SNII was cash that was assumed at historical costs. Separately, the Company also assumed warrants that were deemed to be derivatives and met liability classification subject to fair value adjustment measurements upon closing of the Business Combination (the “Closing”). No goodwill or other intangible assets were recorded because of the Business Combination. While SNII was the legal acquirer in the Business Combination because Legacy Rigetti was deemed the accounting acquirer, the historical financial statements of Legacy Rigetti became the historical financial statements of the combined company, upon the consummation of the Business Combination.

​

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“U.S” and such accounting principles, “GAAP”) for complete financial statements due to the permitted exclusion of certain disclosures for interim reporting. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary under GAAP for a fair presentation of results for the interim periods presented have been included. As a result of displaying amounts in thousands, rounding differences may exist in the condensed consolidated financial statements and footnote tables. The results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the results to be expected for the year ending December 31, 2025 or for other interim periods or future years.

​

The condensed consolidated balance sheet as of December 31, 2024, included herein, is derived from the audited consolidated financial statements as of that date, however, it does not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 7, 2025.

​

Principles of Consolidation

​

The accompanying condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

8

Table of Contents

Emerging Growth Company

Following the Business Combination, the Company qualifies as an emerging growth company (‘‘EGC’’) as defined in the Jumpstart our Business Startups (‘‘JOBS’’) Act. The JOBS Act permits companies with EGC status to take advantage of an extended transition period to comply with new or revised accounting standards, delaying the adoption of these accounting standards until they apply to private companies. The Company intends to use this extended transition period to enable it to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date the Company (i) is no longer an EGC or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting standards as of public company effective dates.

​

On June 30, 2025, the last business day of the Company’s second fiscal quarter in 2025, the aggregate market value of the voting and non-voting common equity of the Company held by non-affiliates exceeded $700.0 million. Accordingly, under the current rules of the SEC, the Company will be deemed to be a “large accelerated filer” as of December 31, 2025. As such, the Company will no longer (i) qualify as an EGC under the rules of the SEC, (ii) be eligible to take advantage of the extended transition period for the adoption of new or revised accounting pronouncements available to an EGC beginning with the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2025 and (iii) be exempt from providing an auditor’s attestation report on internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act. In addition, under the current rules of the SEC, the Company will no longer be eligible to take advantage of the scaled disclosures available to smaller reporting companies beginning with its Quarterly Report on Form 10-Q for the first quarter of 2026.

​

Significant Accounting Policies

​

There were no material changes to the significant accounting policies disclosed in “Note 2 – Summary of Significant Accounting Policies” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 7, 2025.

​

Use of Estimates

​

The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as reported amounts of revenues and expenses during the reporting period. Such management estimates include, but are not limited to, the fair value of share-based awards, the fair value of derivative warrant liabilities, the fair value of Sponsor Vesting Shares issued in connection with the Business Combination, accrued liabilities and contingencies, depreciation and amortization periods, revenue recognition and accounting for income taxes. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment and adjusts when facts and circumstances dictate. These estimates are based on information available as of the date of the condensed consolidated financial statements; therefore, actual results could differ from those estimates.

​

Risks and Uncertainties

​

The Company is subject to a number of risks similar to those of other companies of similar size in its industry, including, but not limited to, the need for successful development of products, the potential need for additional capital (or financing) in the future, competition from substitute products and services from larger companies, protection of proprietary technology, patent litigation, dependence on key individuals, and risks associated with changes in information technology.

​

Based on the Company’s forecasts, the Company believes that its existing cash and cash equivalents and available for sale investments should be sufficient to meet its anticipated operating cash needs for at least the next 12 months from the issuance date of these financial statements based on the Company’s current business plan and expectations and assumptions considering current macroeconomic conditions.

​

Macroeconomic Conditions

Results of the Company’s operations have varied and may continue to vary based in part on the impact of changes in the domestic or global economy. Negative conditions in the general economy both in the United States and abroad, including conditions resulting from changes in gross domestic product growth, inflation, financial and credit market fluctuations, supply chain constraints, international trade policies including tariffs and export controls, national security interests, pandemics, political turmoil, natural catastrophes, warfare, and terrorist attacks in the United States or elsewhere, could negatively affect the Company’s business, including progress toward the development of quantum computing by increasing the cost of materials and components and our operating costs. It is not possible at this time to estimate the long-term impact that these and related events could have on the Company’s business, as the impact will depend on future developments, which are highly uncertain and cannot be predicted.

9

Table of Contents

Recently Adopted Accounting Pronouncements

​

In June 2022, the Financial Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-03- Fair Value Measurement (Topic 820): “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The FASB issued this update (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. ASU 2022-03 was effective for the Company for annual periods beginning after December 15, 2024, and interim periods within those fiscal years, with early adoption permitted. The Company determined that the adoption of this standard did not have an impact on the condensed consolidated financial statements.

​

Recently Issued Accounting Pronouncements Not Yet Adopted

​

In December 2023, the FASB issued ASU 2023-09, “Income Taxes - Improvements to Income Tax Disclosures” requiring enhancements and further transparency to certain income tax disclosures, most notably the tax rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company for annual periods beginning after December 15, 2024 on a prospective basis. Retrospective application is also permitted. The Company is still evaluating the impact of this pronouncement on the consolidated financial statements.

​

In November 2024, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses,” which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. ASU 2024-03 is effective for the Company for annual periods beginning after December 15, 2026, and interim reporting periods within annual periods beginning after December 15, 2027. Early adoption is permitted. The Company is still evaluating the impact of this pronouncement on the condensed consolidated financial statements.

​

In May 2025, the FASB issued ASU 2025-04, “Compensation-Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to Share-Based Consideration Payable to a Customer,” which provides clarifying guidance on the accounting for share-based consideration payable to a customer. ASU 2025-04 is effective for the Company for annual periods beginning after December 31, 2026. Early adoption is permitted using either a full retrospective or modified retrospective transition method. The Company is still evaluating the impact of this pronouncement on the condensed consolidated financial statements.

​

(3) Changes in Stockholders’ Equity

​

Three and Six Months Ended June 30, 2025 and 2024 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  |  | ​ |  |  | ​ |  | ​ | Accumulated | ​ | ​ |  |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | Other | ​ | ​ | ​ | ​ | Total
​ | ​ | Common Stock | ​ | ​ | Paid-In | ​ | Comprehensive | ​ | Accumulated | ​ | Stockholders’
​ | ​ | Shares |  | Amount | ​ | ​ | Capital | ​ | Income (loss) | ​ | Deficit | ​ | Equity
Balance, March 31, 2025 | ​ | 286,975 | ​ | $ | 29 | ​ | $ | 719,315 | ​ | $ | (88) | ​ | $ | (512,128) | ​ | $ | 207,128
Issuance of common stock upon exercise of stock options | ​ | 1,297 | ​ | ​ | — | ​ | ​ | 1,116 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,116
Issuance of common stock upon exercise of common stock warrants | ​ | 10 | ​ | ​ | — | ​ | ​ | 67 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 67
Issuance of common stock upon release of restricted stock units ("RSUs") |  | 2,150 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
Proceeds from sale of common stock from Quanta private placement transaction | ​ | 3,020 | ​ | ​ | — |  |  | 35,000 |  |  | — |  |  | — |  |  | 35,000
Proceeds from sale of common stock through At-The-Market ("ATM") Offering | ​ | 30,310 | ​ | ​ | 3 | ​ | ​ | 346,716 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 346,719
Capitalization of offering costs to equity upon share issuance | ​ | — | ​ | ​ | — | ​ | ​ | (888) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (888)
Stock-based compensation |  | — | ​ | ​ | — |  | ​ | 3,554 |  |  | — |  |  | — |  |  | 3,554
Foreign currency translation gain |  | — |  |  | — |  |  | — |  |  | 156 | ​ |  | — |  |  | 156
Change in unrealized gain on available-for-sale securities |  | — |  |  | — |  |  | — |  |  | 65 |  |  | — |  |  | 65
Net loss |  | — |  |  | — |  |  | — |  |  | — |  |  | (39,654) |  |  | (39,654)
Balance, June 30, 2025 |  | 323,762 | ​ | $ | 32 | ​ | $ | 1,104,880 | ​ | $ | 133 | ​ | $ | (551,782) | ​ | $ | 553,263

​

10

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  |  | ​ |  |  | ​ |  | Accumulated |  | ​ | ​ |  |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | Other | ​ | ​ | ​ | ​ | Total
​ | ​ | Common Stock | ​ | Paid-In | ​ | Comprehensive | ​ | Accumulated | ​ | Stockholders’
​ | ​ | Shares |  | Amount | ​ | Capital | ​ | Income | ​ | Deficit | ​ | Equity
Balance, December 31, 2024 | ​ | 283,547 | ​ | $ | 29 | ​ | $ | 681,202 | ​ | $ | 105 | ​ | $ | (554,747) | ​ | $ | 126,589
Issuance of common stock upon exercise of stock options | ​ | 1,595 | ​ | ​ | — | ​ | ​ | 1,443 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,443
Issuance of common stock upon exercise of common stock warrants | ​ | 56 | ​ | ​ | — | ​ | ​ | 733 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 733
Issuance of common stock upon release of RSUs |  | 5,234 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
Proceeds from sale of common stock from Quanta private placement transaction | ​ | 3,020 | ​ | ​ | — | ​ | ​ | 35,000 | ​ | ​ | — |  |  | — | ​ | ​ | 35,000
Proceeds from sale of common stock through ATM Offering | ​ | 30,310 | ​ | ​ | 3 | ​ | ​ | 346,716 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 346,719
Vesting of Promote Sponsor Vesting Shares | ​ | — | ​ | ​ | — | ​ | ​ | 32,946 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 32,946
Capitalization of offering costs to equity upon share issuance | ​ | — | ​ | ​ | — | ​ | ​ | (888) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (888)
Stock-based compensation |  | — | ​ | ​ | — |  | ​ | 7,728 |  |  | — |  |  | — |  |  | 7,728
Foreign currency translation loss |  | — |  |  | — |  |  | — |  |  | (29) | ​ |  | — |  |  | (29)
Change in unrealized gain on available-for-sale securities |  | — |  |  | — |  |  | — |  |  | 57 |  |  | — |  |  | 57
Net income |  | — |  |  | — |  |  | — |  |  | — |  |  | 2,965 |  |  | 2,965
Balance, June 30, 2025 |  | 323,762 | ​ | $ | 32 | ​ | $ | 1,104,880 | ​ | $ | 133 | ​ | $ | (551,782) | ​ | $ | 553,263

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  |  | ​ |  |  | ​ |  | Accumulated |  | ​ | ​ |  |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | Other | ​ | ​ | ​ | ​ | Total
​ | ​ | Common Stock | ​ | Paid-In | ​ | Comprehensive | ​ | Accumulated | ​ | Stockholders’
​ | ​ | Shares |  | Amount | ​ | Capital | ​ | Income | ​ | Deficit | ​ | Equity
Balance, March 31, 2024 |  | 165,311 | ​ | $ | 16 | ​ | $ | 489,955 | ​ | $ | 138 | ​ | $ | (374,532) | ​ | $ | 115,577
Issuance of common stock upon exercise of stock options | ​ | 31 | ​ | ​ | — | ​ | ​ | 8 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 8
Issuance of common stock upon release of RSUs | ​ | 1,478 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Proceeds from sale of common stock through ATM Offering | ​ | 12,777 | ​ | ​ | 1 | ​ | ​ | 15,801 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 15,802
Capitalization of deferred offering costs to equity upon share issuance | ​ | — | ​ | ​ | — | ​ | ​ | (80) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (80)
Stock-based compensation | ​ | — | ​ | ​ | — | ​ | ​ | 3,287 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,287
Foreign currency translation loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (17) | ​ | ​ | — | ​ | ​ | (17)
Change in unrealized loss on available-for-sale securities | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2 | ​ | ​ | — | ​ | ​ | 2
Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (12,421) | ​ | ​ | (12,421)
Balance, June 30, 2024 |  | 179,597 | ​ | $ | 17 | ​ | $ | 508,971 | ​ | $ | 123 | ​ | $ | (386,953) | ​ | $ | 122,158

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  |  | ​ |  |  | ​ |  | Accumulated |  |  | ​ |  |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | Other | ​ | ​ | ​ | ​ | Total
​ | ​ | Common Stock | ​ | Paid-In | ​ | Comprehensive | ​ | Accumulated | ​ | Stockholders’
​ | ​ | Shares |  | Amount | ​ | Capital | ​ | Income | ​ | Deficit | ​ | Equity
Balance, December 31, 2023 |  | 147,066 | ​ | $ | 14 | ​ | $ | 463,089 | ​ | $ | 244 | ​ | $ | (353,759) | ​ | $ | 109,588
Issuance of common stock upon exercise of stock options | ​ | 250 | ​ | ​ | — | ​ | ​ | 68 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 68
Issuance of common stock upon release of RSUs | ​ | 2,801 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Proceeds from sale of common stock through Purchase Agreement - B. Riley | ​ | 10,057 | ​ | ​ | 1 | ​ | ​ | 12,837 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 12,838
Proceeds from sale of common stock through ATM Offering | ​ | 19,423 | ​ | ​ | 2 | ​ | ​ | 26,831 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 26,833
Capitalization of deferred offering costs to equity upon share issuance | ​ | — | ​ | ​ | — | ​ | ​ | (132) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (132)
Stock-based compensation | ​ | — | ​ | ​ | — | ​ | ​ | 6,278 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 6,278
Foreign currency translation loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (105) | ​ | ​ | — | ​ | ​ | (105)
Change in unrealized loss on available-for-sale securities | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (16) | ​ | ​ | — | ​ | ​ | (16)
Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (33,194) | ​ | ​ | (33,194)
Balance, June 30, 2024 |  | 179,597 | ​ | $ | 17 | ​ | $ | 508,971 | ​ | $ | 123 | ​ | $ | (386,953) | ​ | $ | 122,158

​

​

​

​

​

11

Table of Contents

(4) Investments

​

All investments in fixed income securities are classified as cash equivalents or available-for-sale in the condensed consolidated balance sheets based on the underlying maturity date of each investment. Fixed income securities are recorded at their estimated fair value. The amortized cost, gross unrealized holding gains and losses included in accumulated other comprehensive income and the fair value of the fixed income securities as of June 30, 2025 and December 31, 2024 are presented in the tables below (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, 2025 | ​
​ |  | Amortized |  | Unrealized |  | Unrealized |  | Fair | ​
​ |  | Cost |  | Gains |  | Losses |  | Value | ​
Cash equivalents: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds | ​ | $ | 23,697 | ​ | $ | — | ​ | $ | — | ​ | $ | 23,697 | ​
Cash equivalents | ​ | $ | 23,697 | ​ | $ | — | ​ | $ | — | ​ | $ | 23,697 | ​
Available-for-sale investments-short-term: | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​
U.S. treasury securities | ​ | $ | 368,519 | ​ | $ | 73 | ​ | $ | (36) | ​ | $ | 368,556 | ​
Available-for-sale investments – short-term | ​ | $ | 368,519 | ​ | $ | 73 | ​ | $ | (36) | ​ | $ | 368,556 | ​
Available-for-sale investments-long-term: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasury securities | ​ | $ | 145,806 | ​ | $ | 97 | ​ | $ | — | ​ | $ | 145,903 | ​
Available-for-sale investments – long-term | ​ | $ | 145,806 | ​ | $ | 97 | ​ | $ | — | ​ | $ | 145,903 | ​

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2024
​ |  | Amortized |  | Unrealized |  | Unrealized |  | Fair
​ |  | Cost |  | Gains |  | Losses |  | Value
Cash equivalents: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds | ​ | $ | 29,806 | ​ | $ | — | ​ | $ | — | ​ | $ | 29,806
U.S. treasury security | ​ | ​ | 24,835 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 24,835
Cash equivalents | ​ | $ | 54,641 | ​ | $ | — | ​ | $ | — | ​ | $ | 54,641
Available-for-sale investments-short-term: | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
U.S. treasury securities | ​ | $ | 124,352 | ​ | $ | 69 | ​ | $ | (1) | ​ | $ | 124,420
Available-for-sale investments – short-term | ​ | $ | 124,352 | ​ | $ | 69 | ​ | $ | (1) | ​ | $ | 124,420
Available-for-sale investments-long-term: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasury security | ​ | $ | 25,059 | ​ | $ | 9 | ​ | $ | — | ​ | $ | 25,068
Available-for-sale investments – long-term | ​ | $ | 25,059 | ​ | $ | 9 | ​ | $ | — | ​ | $ | 25,068

​

The Company invests in highly rated investment grade debt securities. As of June 30, 2025, all of the Company’s available-for-sale securities have final maturities of one year or less, except for five U.S. treasury securities classified as long-term with final maturities extending through November 15, 2026. The Company reviews the individual securities that have unrealized losses on a regular basis. The Company evaluates whether it has the intention to sell any of these investments and whether it is more likely than not that it will be required to sell any of them before recovery of the amortized cost basis. Neither of these criteria were met as of June 30, 2025 or December 31, 2024.

​

The Company additionally evaluates whether the decline in fair value of the securities below their amortized cost basis is related to credit losses or other factors. Based on this evaluation, the Company determined that the unrealized losses for its available-for-sale securities were primarily attributable to changes in interest rates and non-credit-related factors.

​

Accordingly, the Company determined that none of the unrealized losses were other-than-temporary, and that recognition of an impairment charge was not required as of June 30, 2025 or December 31, 2024. As of June 30, 2025, there were eight securities with an aggregate market value of $186.2 million that were in an unrealized loss position. The cumulative loss related to these securities was less than $0.1 million. None of the Company’s available-for-sale securities have been in an unrealized loss position for more than one year. No available-for-sale securities were sold during the six months ended June 30, 2025 or June 30, 2024.

​

See Note 5 for additional information regarding the fair value of the Company’s investments.

​

12

Table of Contents

(5) | Fair Value Measurements

​

The Company reports all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring basis. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The level in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest-level input that is significant to the fair value measurement in its entirety. The three levels of the fair value hierarchy are as follows:

​

Level 1—Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

​

Level 2—Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

​

Level 3—Inputs are unobservable inputs for the asset or liability.

​

The following tables present the fair value hierarchy used to measure the Company’s financial assets and liabilities as of June 30, 2025 and December 31, 2024, respectively (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, 2025
​ |  | Level 1 |  | Level 2 |  | Level 3
Assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash equivalents: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds | ​ | $ | 23,697 | ​ | $ | — | ​ | $ | —
Short-term investments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasury securities | ​ | ​ | 58,135 | ​ | ​ | 310,421 | ​ | ​ | —
Long-term investments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasury securities | ​ | ​ | — | ​ | ​ | 145,903 | ​ | ​ | —
Total Assets | ​ | $ | 81,832 | ​ | $ | 456,324 | ​ | $ | —
Liabilities: | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
Derivative warrant liability – Public Warrants | ​ | $ | 48,680 | ​ | $ | — | ​ | $ | —
Derivative warrant liability – Private Warrants | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 11,436
Earn-out liabilities | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 6,371
Total Liabilities | ​ | $ | 48,680 | ​ | $ | — | ​ | $ | 17,807

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | December 31, 2024
​ |  | Level 1 |  | Level 2 |  | Level 3
Assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash equivalents: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds | ​ | $ | 29,806 | ​ | $ | — | ​ | $ | —
U.S. treasury security | ​ | ​ | — | ​ | ​ | 24,835 | ​ | ​ | —
Short-term investments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasury securities | ​ | ​ | — | ​ | ​ | 124,420 | ​ | ​ | —
Long-term investments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasury security | ​ | ​ | — | ​ | ​ | 25,068 | ​ | ​ | —
Total Assets | ​ | $ | 29,806 | ​ | $ | 174,323 | ​ | $ | —
Liabilities: | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
Derivative warrant liability – Public Warrants | ​ | $ | 70,265 | ​ | $ | — | ​ | $ | —
Derivative warrant liability – Private Warrants | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 22,830
Earn-out liabilities | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 45,897
Total Liabilities | ​ | $ | 70,265 | ​ | $ | — | ​ | $ | 68,727

​

As of June 30, 2025 and December 31, 2024, the Company has recorded the following financial instruments subject to fair value measurements: 1) Derivative warrant liabilities—Public Warrants and Private Warrants, 2) Money market funds, 3) U.S. treasury securities and 4) Earn-out liabilities.

​

13

Table of Contents

The fair value of the Public Warrants, money market funds and on-the-run U.S. treasury securities have been measured based on their observable listed prices, a Level 1 measurement. The fair value of the Company’s Level 2 financial assets are determined by using inputs based on quoted market prices for similar instruments.

​

All other financial instruments are classified as Level 3 instruments as they all include unobservable inputs. The Private Warrants are measured at fair value using a Black Scholes model. The fair value of the Earn-out liabilities are estimated using a Monte Carlo simulation model. The Company estimates the volatility of its Private Warrants and Earn-out liabilities based on the historical volatility of the Company’s Common Stock.

​

During the six months ended June 30, 2025, the vesting condition for the Promote Sponsor Vesting Shares (as defined below) was satisfied, and the underlying earn-out liability (Refer to Note 8 for Earn-out liabilities) was adjusted to fair value using the closing market price of the Company’s Common Stock on the vesting date. The earn-out liability for the Promote Sponsor Vesting Shares as of the February 6, 2025 vesting date of $32.9 million was recorded to additional paid-in capital.

​

Previously, the Company used the implied volatility of its Public Warrants in its valuation models for the Private Warrants and Earn-out liabilities. As of December 31, 2024, the Company used the historical volatility of its Common Stock for these valuation models because the implied volatility of the Public Warrants was no longer meaningful due to the rapid increase in the price of the Public Warrants during the fourth quarter of 2024. There were no other changes in fair value measurement techniques during the six months ended June 30, 2025 or June 30, 2024.

​

During the three and six months ended June 30, 2025, the number of Private Warrants (a Level 3 measurement) converted to Public Warrants (a Level 1 measurement) were 29,599 and 575,000, respectively. As of the date of conversion, the favorable impact of the transfer of the Private Warrants to Public Warrants on the Company’s net income (loss) for the three and six months ended June 30, 2025, was $0.1 million and $3.4 million, respectively. Current estimates of fair value may differ from the amounts presented.

​

A summary of the changes in the fair value of the Company’s Level 3 financial instruments during the six months ended June 30, 2025, and June 30, 2024 is as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Derivative |  | ​
​ | ​ | Warrant Liability - | ​ | Earn-out
​ |  | Private Warrants |  | Liabilities
Balance – December 31, 2024 | ​ | $ | 22,830 | ​ | $ | 45,897
Change in fair value - three months ended March 31, 2025 | ​ | ​ | (7,760) | ​ | ​ | (8,837)
Vesting of Promote Sponsor Vesting Shares | ​ | ​ | — | ​ | ​ | (32,946)
Transfer of Private Warrants to Public Warrants - three months ended March 31, 2025 | ​ | ​ | (7,316) | ​ | ​ | —
Change in fair value - three months ended June 30, 2025 | ​ | ​ | 3,906 | ​ | ​ | 2,257
Transfer of Private Warrants to Public Warrants - three months ended June 30, 2025 | ​ | ​ | (224) | ​ | ​ | —
Balance – June 30, 2025 | ​ | $ | 11,436 | ​ | $ | 6,371
​ | ​ | ​ | ​ | ​ | ​ | ​
Balance – December 31, 2023 | ​ | $ | 1,604 | ​ | $ | 2,155
Change in fair value - three months ended March 31, 2024 | ​ | ​ | 1,505 | ​ | ​ | 1,621
Change in fair value - three months ended June 30, 2024 | ​ | ​ | (1,145) | ​ | ​ | (1,315)
Balance – June 30, 2024 | ​ | $ | 1,964 | ​ | $ | 2,461

​

​

(6) | Financing Arrangements

​

Loan and Security Agreement

​

On June 21, 2024, (the “Amendment Date”), the Company entered into the Amended and Restated Loan and Security Agreement (the “Amended Loan Agreement”), by and between Trinity Capital Inc., as lender (the “Lender”), and Rigetti & Co, LLC and Rigetti Intermediate LLC, as borrowers, which amended and restated in its entirety the Company’s existing loan and security agreement, dated as of March 10, 2021 (as amended from time to time, the “Existing Loan Agreement”). The economic terms and cash flows of the Term Loans (defined below) remain unchanged under the Amended Loan Agreement.

​

Under the Existing Loan Agreement, the Company drew $12.0 million in March 2021, $8.0 million in May 2021, $7.0 million in November 2021 and $5.0 million in January 2022 (collectively, the “Term Loans”). The outstanding principal balance of the Term Loans as of the Amendment Date was $16.2 million. Each Term Loan was to be amortized in equal monthly installments through 48 months following the disbursement date of each Term Loan (each, a “Maturity Date”), with interest at a rate equal to the greater of 11% or the US Prime Rate plus 7.50% per annum, payable monthly.

​

14

Table of Contents

The Company had the right to prepay the outstanding Term Loans, in whole or in part, subject to a prepayment premium that remains unchanged from the Existing Loan Agreement. In addition, the Company was required to pay on the respective Maturity Date, or the date of an earlier prepayment, a final payment fee equal to 2.75% of the aggregate original principal amount of the Term Loans, which remains consistent with the Existing Loan Agreement. The final payment fees were being accreted and amortized into interest expense using the effective interest rate method over the term of the loan.

​

On December 9, 2024, the Company prepaid in full all amounts owed under the Amended Loan Agreement. The Company prepaid an aggregate of $9.5 million in outstanding principal balance, final payment fees of $0.9 million, plus accrued interest and a prepayment premium aggregating $0.1 million.

​

During the three and six months ended June 30, 2024, the Company recorded interest expense of $1.0 million and $2.1 million, respectively, which included accretion of the end-of-term liability, amortization of the commitment fee asset and amortization of debt issuance costs totaling $0.2 million and $0.5 million, respectively. The effective interest rate for all tranches of the debt was approximately 23.1% as of June 30, 2024.

​

​

(7) Warrants

​

Each whole Public Warrant and Private Warrant entitles the holder to purchase one share of Common Stock at a price of $11.50 per whole share, subject to adjustment as discussed below. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of Common Stock. The warrants will expire on March 2, 2027 at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

​

Public Warrants

​

When the price per share of the Company’s Common Stock equals or exceeds $18.00, the Company may redeem the outstanding warrants in whole and not in part, at a price of $0.01 per warrant as follows (except as described herein with respect to the Private Warrants):

| ● | upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and

| ● | if, and only if, the closing price of the shares of the Company’s Common Stock equals or exceeds $18.00 per share on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

​

If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise its warrant prior to the scheduled redemption date. Any such exercise would not be done on a “cashless” basis and would require the exercising warrant holder to pay the exercise price in cash for each warrant being exercised. The price of the shares of the Company’s Common Stock may fall below the $18.00 redemption trigger price as well as the $11.50 warrant exercise price after the redemption notice is issued.

​

When the price per share of the Company’s Common Stock equals or exceeds $10.00, the Company may redeem the outstanding warrants in whole and not in part, at a price of $0.10 per warrant as follows (except as described herein with respect to the Private warrants):

| ● | upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption as described below; and

| ● | if, and only if, the closing price of the Company’s Common Stock equals or exceeds $10.00 per share on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

​

Beginning on the date the notice of redemption is given until the warrants are redeemed or exercised, holders may elect to exercise their warrants on a cashless basis and could potentially receive up to a maximum of 0.361 shares of Common Stock per warrant or a minimum of 0.034 shares of Common Stock per warrant. The number of shares of Common Stock that a warrant holder will ultimately receive upon a cashless exercise in connection with a redemption by the Company, is based on the fair market value of the Company’s Common Stock on the redemption date, determined based on the volume weighted average price of the Company’s Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of the warrants, and the number of months that the corresponding redemption date precedes the expiration date of the warrants, as set forth in a table in the warrant agreement.

​

As of June 30, 2025 and December 31, 2024, Public Warrants issued and outstanding were 11,618,076 and 11,082,870, respectively (Refer to Note 5 for fair value measurement). The Public Warrants are accounted for as a derivative liability. The fair value of the Public Warrants is measured at each reporting period based on the listed price for the warrants, with subsequent changes in the fair value recognized in the condensed consolidated statement of operations at each reporting date.

​

15

Table of Contents

During the three and six months ended June 30, 2025, the number of Public Warrants exercised, each for one share of Common Stock in exchange for cash proceeds of $11.50 per share, were 4,248 and 39,794, respectively. During the three months ended June 30, 2025, the proceeds from the warrant exercises and the underlying Public Warrant derivative liabilities on the exercise dates totaled less than $0.1 million. During the six months ended June 30, 2025, the proceeds from the warrant exercises totaled $0.5 million and the underlying Public Warrant derivative liabilities on the exercise dates totaled $0.3 million. The proceeds from the warrant exercises and the underlying Public Warrant derivative liabilities on the exercise dates were recorded to par value of Common Stock and additional paid-in capital.

​

The calculated fair value of the derivative liability for the Public Warrants as of June 30, 2025 and December 31, 2024 were $48.7 million and $70.3 million, respectively. The change in the fair value of the Public Warrants included in the condensed consolidated statement of operations during the three and six months ended June 30, 2025 was a loss of $16.7 million and a gain of $28.8 million, respectively. The change in the fair value of the Public Warrants included in the condensed consolidated statement of operations during the three and six months ended June 30, 2024 was a gain of $1.0 million and a loss of $0.1 million, respectively.

​

Private Warrants

​

The Private Warrants have terms and provisions identical to those of the Public Warrants, including as to exercise price, exercisability and exercise period, except that if the Private Warrants are held by the initial purchasers, or such purchasers’ permitted transferees, then the Private Warrants are not redeemable by the Company and may be exercised for cash or on a cashless basis. If the Private Warrants are held by someone other the initial purchasers or such purchasers permitted transferees, then the Private warrants become Public Warrants and are redeemable by the company and exercisable by such holders on the same basis as the Public Warrants.

​

As of June 30, 2025 and December 31, 2024, Private Warrants issued and outstanding were 1,417,102 and 1,992,102, respectively (Refer to Note 5 for fair value measurement). The Private Warrants are accounted for as a derivative liability. The fair value of the Private Warrants is determined using the Black-Scholes option-pricing model, with subsequent changes in the fair value recognized in the condensed consolidated statements of operations at each reporting date.

​

The calculated fair value of the derivative liability for the Private Warrants as of June 30, 2025 and December 31, 2024 was $11.4 million and $22.8 million, respectively. The change in the fair value of Private Warrants included in the condensed consolidated statements of operations during the three and six months ended June 30, 2025 was a loss of $3.9 million and a gain of $3.9 million, respectively. The change in the fair value of the Private Warrants included in the condensed consolidated statements of operations during the three and six months ended June 30, 2024 was a gain of $1.1 million and a loss of $0.4 million, respectively.

​

Significant inputs into the Black-Scholes option-pricing models used to value the Private Warrants at June 30, 2025 and December 31, 2024 are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  |  | ​ |  |  | ​
Valuation Assumptions |  | June 30, 2025 |  | December 31, 2024
Stock Price | ​ | $ | 11.86 | ​ | $ | 15.26
Strike Price | ​ | $ | 11.50 | ​ | $ | 11.50
Volatility (annual) (%) | ​ | ​ | 149.00% | ​ | ​ | 140.00%
Risk-free rate (%) | ​ | ​ | 3.76% | ​ | ​ | 4.21%
Estimated time to expiration (years) | ​ | ​ | 1.67 | ​ | ​ | 2.17
Dividend yield (%) | ​ | ​ | — | ​ | ​ | —

​

Equity Classified Warrants

​

Series C Preferred Stock Financing Warrants

​

During 2020, a subsidiary of Legacy Rigetti issued and sold an aggregate of 54.5 million shares of its Series C Preferred Stock at a purchase price of $1.15 per share, for an aggregate purchase price of $56.2 million (the “Series C Preferred Stock Financing”). In conjunction with the Series C Preferred Stock Financing, the Company issued a total of 5,248,183 warrants to purchase Class A Common Stock to the Series C investors (the “Series C Warrants”). The Series C Warrants have a $0.01 per share exercise price and a 10-year term to expiration. The Series C Warrants can be exercised for cash or on a cashless basis. The Company determined that the Series C Warrants met the requirements for equity classification under ASC 480 and ASC 815. The Company estimated the fair value of the Series C aarrants using the Black-Scholes model and allocated approximately $1.2 million in proceeds from the Series C Preferred Stock to the value of the Series C Warrants on a relative fair value basis, which was recorded to additional paid in capital.

​

During the three and six months ended June 30, 2025, 5,560 and 16,682 Series C Warrants were exercised, respectively, each for one share of Common Stock, in exchange for cash proceeds of $0.01 per share. The proceeds from the warrant exercises were recorded to par value of Common Stock and additional-paid-in capital. As of June 30, 2025 and December 31, 2024, Series C Warrants issued and outstanding were 777,118 and 793,800, respectively.

16

Table of Contents

Customer Warrant

​

In February 2020, the Company issued a warrant to purchase 2,680,607 shares of Class A Common Stock to a customer in conjunction with a revenue arrangement (the “Customer Warrant”). The Customer Warrant has an exercise price of $1.152 per share and has a 10-year term to expiration. The Customer Warrant vests upon the achievement of certain performance conditions (i.e., sales milestones) defined in the agreement, and upon a change of control, either 50% or 100% of the then unvested Customer Warrant will become fully vested, dependent on the acquiring party in the change of control transaction. The Customer Warrant can be exercised for cash or on a cashless basis. The Customer Warrant was assumed by the Company in connection with the Business Combination and converted into a warrant to purchase shares of Common Stock.

​

The Company followed the guidance in ASC 718 and ASC 606 for the accounting of non-cash consideration payable to a customer. The Company determined that the Customer Warrant met the requirements for equity classification under ASC 718 and measured the Customer Warrant based on its grant date fair value, estimated to be $0.2 million. The Company recorded this amount as a deferred asset and additional paid in capital as of the issuance date, as the Company believes it is probable that all performance conditions (i.e., sales milestones) in the Customer Warrant will be met. As of both June 30, 2025 and December 31, 2024, the deferred asset balance outstanding is approximately $0.1 million, which will be recognized as a reduction in revenue in future periods.

​

The vesting status of the Customer Warrant is as follows:

​

​ | ​ | ​ | ​ | ​
​ |  | June 30, 2025 |  | December 31, 2024
Vested Customer Warrant shares |  | 1,340,297 |  | 1,340,297
Unvested Customer Warrant shares |  | 1,340,310 |  | 1,340,310
​ |  | 2,680,607 |  | 2,680,607

​

(8) Earn-out Liabilities

​

Upon the closing of the Business Combination on March 2, 2022, SNII, Supernova Partners II LLC (the “Sponsor”) and SNII’s directors and officers (collectively the “Sponsor Holders”) subjected certain shares of Common Stock that they own (the “Sponsor Vesting Shares”) to forfeiture for a five-year period following the closing of the Business Combination, with vesting occurring only if thresholds related to the weighted average price of Common Stock are met as described below (the “Earn-out Triggering Events”). Any such shares held by the Sponsor Holders that have not vested by the fifth anniversary of the closing of the Business Combination will be forfeited.

​

Sponsor Vesting Shares – Vesting Provisions:

​

| (i) | 2,479,000 shares of Common Stock held by the Sponsor Holders became unvested and subject to forfeiture as of the closing of the Business Combination and will only vest if, during the five year period following the closing of the Business Combination, the volume weighted average price of Common Stock equals or exceeds $12.50 for any twenty trading days within a period of thirty consecutive trading days (such shares, the “Promote Sponsor Vesting Shares”), and

​

| (ii) | 580,273 shares of Common Stock held by the Sponsor Holders became unvested and subject to forfeiture as of the closing of the Business Combination and will only vest if, during the five year period following the closing of the Business Combination, the volume weighted average price of Common Stock equals or exceeds $15.00 for any twenty trading days within a period of thirty consecutive trading days (such shares, the “Sponsor Redemption-Based Vesting Shares,” and, collectively with the Promote Sponsor Vesting Shares, the “Sponsor Vesting Shares”). Any such shares held by the Sponsor Holders that remain unvested after the fifth anniversary of the closing of the Business Combination will be forfeited.

​

During the six months ended June 30, 2025, the vesting condition for the Promote Sponsor Vesting Shares was satisfied, and the underlying earn-out liability was adjusted to fair value using the closing market price of the Company’s Common Stock on the vesting date. The earn-out liability for the Promote Sponsor Vesting Shares as of the February 6, 2025 (“vesting date”) of $32.9 million was recorded to additional paid-in capital.

​

As of June 30, 2025, the vesting condition for the Sponsor Redemption-Based Vesting shares remained unsatisfied. As of the market close on August 8, 2025, the volume weighted average price of the Company’s Common Stock equaled or exceeded $15.00 for 16 days out of the last 18 trading days. If the volume weighted average price of the Company’s Common Stock were to equal or exceed $15.00 for 4 days out of the next 12 trading days commencing on August 11, 2025, the vesting condition for the Sponsor Redemption-Based Vesting shares would be satisfied.

​

17

Table of Contents

The Earn-out liabilities related to the unvested Sponsor Vesting Shares are adjusted to fair value each reporting period using the Monte Carlo simulation model until such time as the Earn-Out Triggering Events are achieved or the Sponsor Vesting Shares are forfeited.

​

The calculated fair value of the Earn-out liabilities with respect to the unvested Sponsor Vesting Shares as of June 30, 2025 and December 31, 2024 were $6.4 million and $45.9 million, respectively. The change in the fair value of the Earn-out liabilities included in the condensed consolidated statements of operations during the three and six months ended June 30, 2025 was a loss of $2.3 million and a gain of $6.6 million, respectively. The change in the fair value of the Earn-out liabilities included in the condensed consolidated statements of operations during the three and six months ended June 30, 2024 was a gain of $1.3 million and a loss of $0.3 million, respectively.

​

Significant inputs into the Monte Carlo simulation models as of June 30, 2025 and December 31, 2024 were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
Valuation Assumptions |  | June 30, 2025 |  | December 31, 2024
Stock price | ​ | $ | 11.86 | ​ | $ | 15.26
Simulated trading days | ​ | ​ | 421 | ​ | ​ | 542
Annual volatility (%) | ​ | ​ | 149.00% | ​ | ​ | 140.00%
Risk-free rate (%) | ​ | ​ | 3.76% | ​ | ​ | 4.21%
Estimated time to expiration (in years) | ​ | ​ | 1.67 | ​ | ​ | 2.17

​

​

(9) Stockholders’ Equity

​

As of June 30, 2025, the Company has reserved the following shares of Common Stock for issuance upon the conversion, exercise or vesting of the underlying instruments:

​

​ | ​ | ​
​ |  | Common Stock
Common Stock warrants |  | 16,528,051
Stock-Based Awards—RSUs Outstanding |  | 6,544,122
Stock-Based Awards—Options Outstanding |  | 6,536,637
Total |  | 29,608,810

​

At-the-Market Offerings

​

May 2025 Sales Agreement with Jefferies, LLC

​

On May 29, 2025, the Company entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies, LLC (the “Agent”) with respect to an At-the-Market offering program, pursuant to which the Company sold, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of $350 million (the “ATM Offering”). The shares offered and sold in the ATM Offering were issued and sold pursuant to the Company’s automatic shelf registration statement on Form S-3 and the related prospectus supplement, which the Company filed with the SEC on May 29, 2025. The Company paid the Agent a commission of up to 3% of the gross proceeds of the shares sold under the Sales Agreement, and the Company agreed to provide the Agent with customary indemnification rights. The Sales Agreement contains customary representations and warranties and conditions to the sale of the shares pursuant thereto.

​

During the three months ended June 30, 2025, the Company raised gross proceeds of $350 million from the sale of 30,309,780 shares of its Common Stock pursuant to the Sales Agreement, at a weighted average price of $11.55 per share, which represented the full amount of shares available for sale under the Sales Agreement. The net proceeds from the Sales Agreement during the three months ended June 30, 2025 were $346.7 million, after deducting Agent commissions totaling $3.3 million. As of June 30, 2025, there were no remaining shares available for sale pursuant to the Sales Agreement.

​

March 2024 Sales Agreement with B. Riley Securities, Inc. and Needham & Company, LLC

​

On March 15, 2024, the Company entered into an At-the-Market Sales Agreement (the “Prior ATM Agreement”) with B. Riley Securities, Inc. and Needham & Company, LLC pursuant to which the Company sold, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of $100 million.

​

During the three months ended June 30, 2024, the Company raised gross proceeds of $16.2 million from the sale of 12,777,393 shares of its Common Stock pursuant to the Prior ATM Agreement, at a weighted average price of $1.27 per share. During the six months ended June 30, 2024, the Company raised gross proceeds of $27.5 million from the sale of 19,423,375 shares of its Common Stock pursuant to the Prior ATM Agreement, at a weighted average price of $1.42 per share.

18

Table of Contents

The net proceeds from the Prior ATM offering during the three and six months ended June 30, 2024 were $15.8 million and $26.8 million, respectively, after deducting sales agent commissions of $0.4 million and $0.7 million, respectively. As of June 30, 2025, there were no remaining shares available for sale under the Prior ATM Agreement.

Common Stock Purchase Agreement

​

The Company entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with B. Riley Principal Capital II, LLC (“B. Riley”) on August 11, 2022 pursuant to which the Company was able to issue and sell to B. Riley the lesser of i) $75.0 million in aggregate gross purchase price of newly issued shares of the Company’s Common Stock or ii) an amount not to exceed 23,648,889 shares of Common Stock (such number of shares equal to approximately 19.99% of the aggregate number of shares of Common Stock issued and outstanding immediately prior to the execution of the agreement and inclusive of 171,008 shares of Common Stock issued to B. Riley on August 11, 2022 as consideration for entering into the Purchase Agreement).

​

In consideration of the parties entering into the foregoing agreement, the parties also entered into a Registration Rights Agreement on August 11, 2022, pursuant to which the Company provided B. Riley with registration rights with respect to such Common Stock and pursuant to which the Company filed a registration statement covering the resale of such Common Stock.

​

During the three months ended June 30, 2024, the Company did not sell any Common Stock under the Purchase Agreement. During the six months ended June 30, 2024, the Company received net proceeds of $12.8 million from the issuance and sale of 10,056,799 shares of Common Stock to B. Riley under the Purchase Agreement. As of June 30, 2025, there were no remaining shares available for sale under the Purchase Agreement; as a result, the Purchase Agreement has terminated.

(10) Share-Based Compensation

2013 Equity Incentive Plan

​

In 2013, the Company adopted the 2013 Equity Incentive Plan ( the “2013 Plan”) which provided for the grant of qualified incentive stock options (“ISOs”) and nonqualified stock options (“NSOs”), restricted stock, restricted stock units (“RSUs”) or other awards to the Company’s employees, officers, directors, advisors, and outside consultants. After the Business Combination became effective on March 2, 2022, no additional awards were issued under the 2013 Plan. Awards outstanding under the 2013 Plan will continue to be governed by such plan; however, the Company will not grant any further awards under the 2013 Plan.

​

2022 Equity Incentive Plan

​

In connection with the Business Combination, the shareholders approved the Rigetti Computing, Inc. 2022 Equity Incentive Plan (the “2022 Plan”) which provides for the grant of ISOs, NSOs, stock appreciation rights, restricted stock awards, RSUs, performance awards and other forms of awards to employees, directors, and consultants, including employees and consultants of the Company’s affiliates. As of June 30, 2025, there were 32,403,747 shares of Common Stock reserved for issuance under the 2022 Plan, of which 20,817,292 shares remain available for future issuance. The number of shares reserved for issuance under the 2022 Plan will automatically increase on January 1st of each year for a period of nine years commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to 5% of the total number of shares of Common Stock of all classes outstanding on a fully diluted basis on December 31st of the preceding year; provided, however, that the board of directors of the Company may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock. Accordingly, as of January 1, 2025, the number of shares of Common Stock reserved for issuance under the “2022 Plan” was increased by 15,972,015 shares.

​

Stock Option Activity

​

The following is a summary of stock option activity during the six months ended June 30, 2025:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Weighted |  | Weighted- |  |  | ​
​ | ​ | ​ | ​ | Average | ​ | Average | ​ | Aggregate
​ | ​ | ​ | ​ | Exercise | ​ | Contractual | ​ | Intrinsic
​ | ​ | Options Outstanding | ​ | Price Per Share | ​ | Life (in years) | ​ | Value (in thousands)
Outstanding, December 31, 2024 |  | 8,131,235 | ​ | $ | 1.01 |  | 8.04 | ​ | $ | 115,878
Granted |  | — | ​ | ​ | — |  | ​ |  |  | ​
Exercised |  | (1,594,598) | ​ | ​ | 0.90 |  | ​ |  | ​ | 17,441
Forfeited and expired |  | — | ​ | ​ | — |  | ​ |  |  | ​
Outstanding and expected to vest, June 30, 2025 | ​ | 6,536,637 | ​ | $ | 1.03 | ​ | 7.63 | ​ | $ | 70,763
Exercisable, June 30, 2025 |  | 3,454,324 | ​ | $ | 0.79 |  | 6.74 | ​ | $ | 38,255

​

19

Table of Contents

The Company’s outstanding stock options generally have exercise prices equal to fair market value on the date of grant, expire after ten years and have service-based vesting conditions ranging from 1-5 years, except that 500,000 stock options granted in 2022 had a market-based vesting condition tied to the Company’s Common Stock price. The vesting condition with respect to the market-based stock option grants was satisfied in January 2025. The intrinsic value of an option is the amount by which the market price of the underlying Common Stock exceeds the option’s exercise price. The intrinsic value of stock options exercised during the six months ended June 30, 2025 and June 30, 2024 was $17.4 million and $0.3 million, respectively. The Company received proceeds from stock option exercises of $1.4 million and $0.1 million during the six months ended June 30, 2025 and June 30, 2024, respectively.

​

Stock-based compensation expense related to stock options granted to employees was $0.5 million and $1.0 million for the three and six months ended June 30, 2025, respectively. Stock-based compensation expense related to stock options granted to employees was $0.5 million and $0.9 million for the three and six months ended June 30, 2024, respectively. As of June 30, 2025, the unrecognized compensation expense related to unvested stock options was $3.3 million, which is expected to be recognized over a weighted-average period of 1.96 years.

​

Fair Value of Stock Option Grants

​

The fair value of each stock option award is estimated on the grant date using the Black-Scholes option-pricing model. No stock options were granted during the six months ended June 30, 2025. The weighted-average grant date fair value of stock options granted during the six months ended June 30, 2024 was $1.51 per share. The valuation assumptions used as inputs to the Black-Scholes option-pricing model to value the Company’s service-based stock options include expected volatility for the Company’s Common Stock, the expected term of the stock options granted, the assumed dividend yield and the risk free interest rate at the time of grant.

​

For the first nine months of 2024, expected volatility for the Company’s Common Stock was determined based on a blended average of the historical volatility of a peer group of similar public companies, the historical volatility of the Company’s Common Stock and the implied volatility from the Company’s Public Warrants. For the last three months of 2024, expected volatility for the Company’s Common Stock was determined based on a one-third weighting of the historical volatility of a peer group of similar public companies and a two-thirds weighting of the historical volatility of the Company’s Common Stock. The implied volatility from the Company’s Public Warrants was excluded because the calculation did not produce a meaningful result. The Company has not been public for a sufficient length of time to derive expected volatility solely from trading in its Common Stock.

​

The expected term of stock options granted was calculated using the simplified method, which represents the average of the contractual term and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical exercise data for its options to provide a reasonable basis upon which to estimate the expected term.

​

The assumed dividend yield is based upon the Company’s expectation of not paying dividends in the foreseeable future. The risk-free rate is based upon the U.S. Treasury yield curve in effect at the time of grant for the period equivalent to the expected term of the stock option. In determining the exercise prices for stock options granted, the Company’s board of directors has utilized the fair value of the Common Stock as of the grant date.

​

Before the Business Combination, the fair value of the Common Stock had been determined by the board of directors at each award grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company’s financial position and historical financial performance, the status of technological developments within the Company, the composition and ability of the current engineering and management team, an evaluation or benchmark of the Company’s competition, the current business climate in the marketplace, the illiquid nature of the Company’s Common Stock, arm’s-length sales of the Company’s capital stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event, among others.

​

RSUs

​

The following is a summary of RSU activity during the six months ended June 30, 2025:

​

​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted Average
​ | ​ | ​ | ​ | Grant Date Fair
​ |  | Shares |  | Value
Non-vested at December 31, 2024 |  | 11,177,661 | ​ | $ | 1.53
Granted |  | 823,342 | ​ | ​ | 9.08
Vested |  | (5,234,029) | ​ | ​ | 1.66
Forfeited |  | (222,852) | ​ | ​ | 1.54
Non-vested at June 30, 2025 |  | 6,544,122 | ​ | $ | 2.38

​

20

Table of Contents

The Company’s RSUs generally have service-based vesting conditions ranging from 1-4 years, except that 3,850,000 RSUs granted in 2023 had a market-based vesting condition tied to the Company’s stock price. Based upon the terms of such awards, 50% of the shares became vested when the Company’s Common Stock traded at or above $2.00 per share and the other 50% of the shares became vested when the Company’s Common Stock traded at or above $4.00 per share, for 20 out of 30 trading days through the fifth anniversary of the grant date. The $2.00 per share vesting condition was satisfied in December 2024, and the $4.00 per share vesting condition was satisfied in January 2025.

​

The income tax withholding obligation for all RSUs are satisfied through the sale of shares into the market, otherwise known as Sell-To-Cover (“STC”). The STC transaction and the income tax withholding remittance for the market-based RSUs that vested in December 2024 took place on December 30, 2024. The $6.3 million proceeds from the STC were received by the Company on January 2, 2025, and is included in other current assets in the accompanying balance sheet as of December 31, 2024.

​

The aggregate fair value of outstanding RSUs based on the closing share price of the Company’s Common Stock as of June 30, 2025 and June 30, 2024 was $77.6 million and $10.3 million, respectively. The aggregate fair value of RSUs that vested based on the closing price of the Company’s Common Stock on the vesting date during the six months ended June 30, 2025 and June 30, 2024 was $52.7 million and $3.5 million, respectively.

​

Fair Value of RSUs Awards

​

The number of service-based RSUs granted during the six months ended June 30, 2025 and June 30, 2024 was 823,342 and 1,567,515, respectively. The service-based RSUs vest over periods ranging from 1-4 years and require continuous employment. The weighted-average grant date fair value of the service-based RSUs granted during the six months ended June 30, 2025 and June 30, 2024 was $9.08 and $1.46 per share, respectively. The fair value of the service-based RSUs was calculated based on the fair market value of the Company’s Common Stock on the date of grant.

​

Stock-based compensation expense related to RSUs granted to employees was $3.0 million and $6.7 million for the three and six months ended June 30, 2025, respectively. Stock-based compensation expense related to RSUs granted to employees was $2.8 million and $5.5 million for the three and six months ended June 30, 2024, respectively. As of June 30, 2025, the unrecognized compensation expense related to unvested RSUs was $14.7 million, which is expected to be recognized over a weighted-average period of 2.09 years.

​

Summarized Stock-Based Compensation Expenses

​

The table below summarizes total stock-based compensation expenses for the three and six months ended June 30, 2025 and June 30, 2024 (in thousands):

​

:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended June 30, | ​ | Six Months Ended June 30, | ​
​ |  | 2025 |  | 2024 |  | 2025 |  | 2024 | ​
Research and development | ​ | $ | 2,256 | ​ | $ | 2,262 | ​ | $ | 5,277 | ​ | $ | 4,189 | ​
Selling, general and administrative expenses | ​ | ​ | 1,298 | ​ | ​ | 1,025 | ​ | ​ | 2,451 | ​ | ​ | 2,089 | ​
Total stock-based compensation expenses | ​ | $ | 3,554 | ​ | $ | 3,287 | ​ | $ | 7,728 | ​ | $ | 6,278 | ​

​

​

​

(11) | Revenue Recognition

The following tables depict the disaggregation of revenue according to the type of good or service and timing of transfer of goods or services for the three and six months ended June 30, 2025 and June 30, 2024 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended June 30, | ​ | Six Months Ended June 30, | ​
​ |  | 2025 |  | 2024 |  | 2025 |  | 2024 | ​
Collaborative research and professional services | ​ | $ | 1,711 | ​ | $ | 3,081 | ​ | $ | 3,043 | ​ | $ | 5,918 | ​
Access to quantum computing systems | ​ | ​ | 90 | ​ | ​ | 5 | ​ | ​ | 230 | ​ | ​ | 220 | ​
​ | ​ | $ | 1,801 | ​ | $ | 3,086 | ​ | $ | 3,273 | ​ | $ | 6,138 | ​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended June 30, | ​ | Six Months Ended June 30,
​ |  | 2025 |  | 2024 |  | 2025 |  | 2024
Revenue recognized at a point in time | ​ | $ | — | ​ | $ | 523 | ​ | $ | — | ​ | $ | 523
Revenue recognized over time |  |  | 1,801 | ​ |  | 2,563 | ​ |  | 3,273 |  |  | 5,615
​ | ​ | $ | 1,801 | ​ | $ | 3,086 | ​ | $ | 3,273 | ​ | $ | 6,138

​

21

Table of Contents

Selected condensed consolidated balance sheet line items that reflect accounts receivable, contract assets and liabilities as of June 30, 2025, December 31, 2024 and December 31, 2023 were as follows (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, 2025 |  | December 31, 2024 |  | December 31, 2023
Trade receivables | ​ | $ | 342 | ​ | $ | 1,498 | ​ | $ | 2,650
Unbilled receivables | ​ | $ | 1,411 | ​ | $ | 929 | ​ | $ | 2,379
Current portion of deferred revenue | ​ | $ | (118) | ​ | $ | (113) | ​ | $ | (343)
Deferred revenue, less current portion | ​ | $ | (698) | ​ | $ | (698) | ​ | $ | —

​

Changes in deferred revenue from contracts with customers were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six Months Ended June 30, | ​
​ |  | 2025 |  | 2024 | ​
Balance at beginning of period | ​ | $ | (811) | ​ | $ | (343) | ​
Deferral of revenue | ​ | ​ | (110) | ​ | ​ | (712) | ​
Recognition of deferred revenue | ​ | ​ | 105 | ​ | ​ | 219 | ​
Total deferred revenue at end of period | ​ | $ | (816) | ​ | $ | (836) | ​
Current portion of deferred revenue | ​ | $ | (118) | ​ | $ | (836) | ​
Deferred revenue, less current portion | ​ | $ | (698) | ​ | $ | — | ​

​

Amounts recognized as revenue from beginning contract liabilities during the three and six months ended June 30, 2025 was an immaterial amount and $0.1 million, respectively. Amounts recognized as revenue from beginning contract liabilities during the three and six months ended June 30, 2024 was an immaterial amount and $0.2 million, respectively. Remaining performance obligations represent the portion of the transaction price that has not yet been satisfied or achieved. As of June 30, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $5.7 million. The Company expects to recognize estimated revenues related to performance obligations that are unsatisfied (or partially satisfied) during the next twelve months, except for remaining performance obligations totaling $0.9 million.

​

The Company has not identified any costs that are incremental to the acquisition of customer contracts that would be capitalized as deferred costs on the balance sheet. Accordingly, the Company does not have any capitalized contract fulfillment costs as of June 30, 2025 or December 31, 2024.

​

(12) Segments, Geographical Information, Concentrations and Significant Customers

​

In addition to consolidated net income (loss), our Chief Operating Decision Maker (CODM), the Chief Executive Officer, reviews and utilizes natural expenses such as employee wages and benefits at a consolidated level and capital expenditures including fixed asset additions to manage the Company’s operations and strategic growth initiatives. The measure of segment assets is reported in the balance sheet as total consolidated assets. The following table sets forth our segment information of revenue, expenses and net income (loss) (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended June 30, | ​ | Six Months Ended June 30,
​ | ​ | 2025 |  | 2024 | ​ | 2025 |  | 2024
Revenue | ​ | $ | 1,801 | ​ | $ | 3,086 | ​ | $ | 3,273 | ​ | $ | 6,138
Less: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Salaries and employee related costs | ​ | ​ | 7,930 | ​ | ​ | 6,721 | ​ | ​ | 16,862 | ​ | ​ | 13,458
Stock-based compensation | ​ | ​ | 3,554 | ​ | ​ | 3,287 | ​ | ​ | 7,728 | ​ | ​ | 6,278
Rent and facilities | ​ | ​ | 1,495 | ​ | ​ | 2,020 | ​ | ​ | 2,834 | ​ | ​ | 3,902
Professional services and legal fees | ​ | ​ | 2,339 | ​ | ​ | 1,625 | ​ | ​ | 5,252 | ​ | ​ | 3,312
Technology & IT costs | ​ | ​ | 1,225 | ​ | ​ | 1,062 | ​ | ​ | 2,548 | ​ | ​ | 2,109
Direct and indirect materials | ​ | ​ | 570 | ​ | ​ | 609 | ​ | ​ | 1,263 | ​ | ​ | 1,015
Depreciation and amortization expense | ​ | ​ | 1,894 | ​ | ​ | 1,547 | ​ | ​ | 3,723 | ​ | ​ | 3,334
Interest expense | ​ | ​ | — | ​ | ​ | 969 | ​ | ​ | — | ​ | ​ | 2,076
Other segment items(1) | ​ | ​ | 22,448 | ​ | ​ | (2,333) | ​ | ​ | (39,902) | ​ | ​ | 3,848
Segment and net income (loss) | ​ | $ | (39,654) | ​ | $ | (12,421) | ​ | $ | 2,965 | ​ | $ | (33,194)

(1)Other segment items include interest income, changes in fair value of derivative warrant liabilities and earnout liabilities and other operational expenses which are reflected in the condensed consolidated statements of operations.

​

22

Table of Contents

The following table presents a summary of our segment fixed asset additions (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended June 30, | ​ | Six Months Ended June 30,
​ | ​ | 2025 |  | 2024 | ​ | 2025 |  | 2024
Quantum computing fridges | ​ | $ | 2,623 | ​ | $ | 2,197 | ​ | $ | 4,334 | ​ | $ | 3,257
Process equipment | ​ | ​ | 219 | ​ | ​ | — | ​ | ​ | 682 | ​ | ​ | 6
Leasehold improvements | ​ | ​ | 110 | ​ | ​ | 34 | ​ | ​ | 194 | ​ | ​ | 51
IT hardware | ​ | ​ | 263 | ​ | ​ | 110 | ​ | ​ | 352 | ​ | ​ | 209
Construction in progress and other assets | ​ | ​ | 1,400 | ​ | ​ | 246 | ​ | ​ | 2,465 | ​ | ​ | 1,047
Total property and equipment | ​ | $ | 4,615 | ​ | $ | 2,587 | ​ | $ | 8,027 | ​ | $ | 4,570

​

The following table presents a summary of revenue by geography (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended June 30, | ​ | Six Months Ended June 30,
​ |  | 2025 |  | 2024 | ​ | 2025 |  | 2024
United States | ​ | $ | 967 | ​ | $ | 2,156 | ​ | $ | 1,352 | ​ | $ | 4,315
Europe | ​ | ​ | 771 |  | ​ | 407 | ​ | ​ | 1,784 | ​ | ​ | 1,300
Asia and others | ​ | ​ | 63 | ​ | ​ | 523 | ​ | ​ | 137 | ​ | ​ | 523
Total revenue | ​ | $ | 1,801 |  | $ | 3,086 | ​ | $ | 3,273 | ​ | $ | 6,138

​

Revenues from external customers are attributed to individual countries based on the physical location in which the services are provided or the particular customer location with whom the Company has contracted.

​

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and trade accounts receivable. The Company’s cash and cash equivalents are placed with high-credit-quality financial institutions, and at times exceed federally insured limits. To date, the Company has not experienced any credit loss relating to its cash and cash equivalents.

​

Significant customers that represent 10% or more of revenue are set forth in the following table:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended June 30, | ​ | Six Months Ended June 30,
​ |  | 2025 | ​ | 2024 |  | 2025 |  | 2024
Customer A |  | * | ​ | 22% | ​ | * | ​ | 19%
Customer B | ​ | 20% | ​ | * | ​ | 17% | ​ | 10%
Customer C |  | 27% | ​ | * | ​ | 15% | ​ | 20%
Customer D |  | 39% | ​ | 11% | ​ | 53% | ​ | 27%
Customer E | ​ | * | ​ | 26% | ​ | * | ​ | *
Customer F |  | * | ​ | 17% | ​ | * | ​ | *

* Customer accounted for less than 10% of revenue in the respective periods.

​

During the three and six months ended June 30, 2025, sales to government entities comprised 91.7% and 90.7% of the Company’s total revenue, respectively. During the three and six months ended June 30, 2024, sales to government entities comprised 79.5% and 88.4% of the Company’s total revenue, respectively.

​

Significant customers that represent 10% or more of accounts receivable are set forth in the following table:

​

​ | ​ | ​ | ​ | ​
​ |  | June 30, 2025 |  | December 31, 2024
Customer A |  | * | ​ | *
Customer B |  | 41% | ​ | 15%
Customer C |  | 26% | ​ | 23%
Customer D | ​ | * | ​ | 26%
Customer E | ​ | * | ​ | 31%
Customer F | ​ | 28% | ​ | *

* Customer accounted for less than 10% of accounts receivable in the respective periods.

​

23

Table of Contents

(13) Net Income (Loss) Per Share

The following table presents the calculations of basic and diluted net income (loss) per share attributable to common stockholders (in thousands, except for per share amounts):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended June 30, | ​ | Six Months Ended June 30,
​ |  | 2025 |  | 2024 |  | 2025 |  | 2024
Numerator: |  |  | ​ | ​ | ​ |  |  |  | ​ | ​ | ​ |
Net income (loss) used in basic computation | ​ | $ | (39,654) | ​ | $ | (12,421) |  | $ | 2,965 | ​ | $ | (33,194)
Less: Vesting of Promote Sponsor Vesting Shares | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (4,363) | ​ | ​ | —
Net loss used in diluted computation | ​ | $ | (39,654) | ​ | $ | (12,421) | ​ | $ | (1,398) | ​ | $ | (33,194)
Denominator: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted-average shares outstanding - basic and diluted | ​ | ​ | 298,254 | ​ | ​ | 171,903 | ​ | ​ | 291,514 | ​ | ​ | 161,705
Net income (loss) per share - basic | ​ | $ | (0.13) | ​ | $ | (0.07) |  | $ | 0.01 | ​ | $ | (0.21)
Net loss per share - diluted | ​ | $ | (0.13) | ​ | $ | (0.07) | ​ | $ | 0.00 | ​ | $ | (0.21)

​

For each of the three and six months ended June 30, 2025 and each of the three and six months ended June 30, 2024, the number of Sponsor Vesting Shares excluded from the computations of basic and diluted net income (loss) per share because the vesting conditions had not been satisfied totaled 580,273 and 3,059,273 shares, respectively.

​

The vesting condition for the Promote Sponsor Vesting Shares was satisfied on February 6, 2025. As of June 30, 2025, the vesting condition for the Sponsor Redemption-Based Vesting shares remained unsatisfied (Refer to Note 8 for Earn-out liabilities). The underlying gain from the change in the fair value of the Promote Sponsor Vesting Shares has been excluded from the fully-diluted computation for the six months ended June 30, 2025 due to resolution of the contingency, resulting in a net loss for purposes of the computation. For the three and six months ended June 30, 2025, the Promote Sponsor Vesting Shares have been included in the computations of basic and diluted net income (loss) per share from the February 6, 2025 vesting date. The Promote Sponsor Vesting Shares were not included in the computation of diluted net loss per share for the six months ended June 30, 2025 from the beginning of the period (January 1, 2025) because their effect would be anti-dilutive.

​

The weighted-average common shares outstanding for the three and six months ended June 30, 2025 include 777,240 and 784,368 weighted-average shares for warrants having an exercise price of $0.01 per share each, respectively. The weighted-average common shares outstanding for each of the three and six months ended June 30, 2024 include 972,578 weighted-average shares for warrants having an exercise price of $0.01 per share each.

​

The Company excluded the following potentially dilutive securities from the computations of diluted net loss per share for the three and six months ended June 30, 2025 and June 30, 2024 because their effect would be anti-dilutive:

​

​ | ​ | ​ | ​ | ​ | ​
​ |  | Six Months Ended June 30, | ​
​ | ​ | 2025 |  | 2024 | ​
Common Stock warrants (1) |  | 14,410,623 |  | 14,450,417 | ​
Stock Options |  | 6,536,637 |  | 9,600,802 | ​
Restricted Stock Units |  | 6,544,122 |  | 8,382,814 | ​
​ |  | 27,491,382 |  | 32,434,033 | ​

(1) | The number of outstanding warrants as of both June 30, 2025 and June 30, 2024 does not include 1,340,310 unvested Customer Warrants.

​

​

(14) | Income Taxes

​

The effective tax rate differs from the statutory rate, primarily due to the Company’s history of incurring losses which have not been benefited, write-off of federal and state net operating loss carryforwards and research and development tax credit carryforwards under Internal Revenue Code (IRC) section 382 limitation, stock-based compensation and other permanent differences, including gains and losses on derivative warrant and earn-out liabilities.

​

The Company has deferred tax assets as a result of temporary differences between the taxable income on its tax returns and GAAP income, R&D tax credit carry forwards and federal and state net operating loss carry forwards. A deferred tax asset generally represents future tax benefits to be received when temporary differences previously reported in the Company’s condensed consolidated financial statements become deductible for income tax purposes, when net operating loss carry forwards could be applied against future taxable income, or when tax credit carry forwards are utilized in the Company’s tax returns.

24

Table of Contents

Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net U.S. federal and state deferred tax assets have been fully offset by a valuation allowance.

​

Under Section 382 of the Internal Revenue Code of 1986, as amended, the Company’s federal net operating loss carryforwards and research and development tax credit carryforwards, and other tax attributes are subject to annual limitation because of prior cumulative changes in the Company’s ownership and may be further limited in the future if additional ownership changes occur. Similar rules apply under state tax laws. These ownership changes limit the amount of net operating loss carryforwards and research and development tax credit carryforwards that can be utilized annually to reduce the Company’s federal and state income tax liabilities, if any. Such annual limitations could result in the expiration of the net operating loss carryforwards and research and development tax credit carryforwards before their utilization.

​

The Company has incurred a cumulative pre-tax loss for the past three years. The Company expects that it will continue to incur losses for income tax purposes for the foreseeable future, and will continue to carry a full valuation allowance for its deferred tax assets. Accordingly, the Company did not record a provision for income taxes for either the three and six months ended June 30, 2025 or the three and six months ended June 30, 2024.

​

On July 4, 2025, new federal tax and budget legislation, known as the “One Big Beautiful Bill Act” (“OBBA”) was signed into law. Any financial impacts from the legislation will be reflected in the Company’s condensed consolidated financial statements during the three months ended September 30, 2025 when the legislation became law. The Company presently does not expect the OBBA to have a material impact on the condensed consolidated financial statements.

​

​

(15) Collaborative Arrangements

​

On February 27, 2025, the Company entered into a Collaboration Agreement (the “Collaboration Agreement”) with Quanta Computer Inc., a Taiwan corporation (“Quanta”). The term of the Collaboration Agreement is for five years, subject to cancellation under certain circumstances.

​

Pursuant to the Collaboration Agreement, during the five year period following February 27, 2025, the Company has agreed it will invest at least $250.0 million in the field of quantum computing, in furtherance of its product roadmap, and Quanta has agreed it will invest at least $250.0 million in the field of quantum computing, and the investment by Quanta will be towards personnel and capital expenditures for developing products and services and manufacturing capability in furtherance of the Company’s product roadmap. No equity or joint venture was formed under the Collaboration Agreement. Costs incurred by the Company under the Collaboration Agreement, consisting of its expenditures for research and development and related capital, will be accounted for in accordance with GAAP as incurred.

​

Under the Collaboration Agreement, the Company will retain all rights, title and ownership to all QPU Technology (as defined in the Collaboration Agreement) and related intellectual property (IP) rights created in the course of activities specified in a statement of work under the Collaboration Agreement. Other than the QPU Technology and IP rights described above, to the extent there is any jointly created, invented or other developed technology in the course of the performance of activities specified in a statement of work under the Collaboration Agreement, the Company and Quanta will jointly own, and each party will hold a one-half undivided interest in, all such joint project technology and all newly-created or newly-arising IP rights with respect thereto.

​

In connection with the Collaboration Agreement, on February 27, 2025, the Company entered into a securities purchase agreement with Quanta, pursuant to which the Company agreed to sell and issue to Quanta in a private placement transaction 3,020,412 shares of its Common Stock at a price per share of approximately $11.59, for an aggregate value of approximately $35.0 million. The price per share was based on the volume weighted-average price of the Company’s Common Stock for the 15 trading days prior to February 27, 2025. The private placement transaction, which was subject to regulatory clearance, closed on April 29, 2025. In connection with the private placement transaction, Quanta entered into a board observer and confidentiality agreement under which it has the option and right to appoint a single representative to attend certain meetings of the board of directors of the Company, subject to exceptions, in a non-voting observer capacity. The securities purchase agreement also contains a lock-up provision prohibiting Quanta from selling any of the shares of the Company’s Common Stock acquired in the securities purchase agreement for a three year period following the closing of the private placement transaction.

25

Table of Contents

​

(16) | Commitments and Contingencies

​

Legal Proceedings

​

From time to time, the Company is party to litigation and other legal proceedings in the ordinary course of business. While the results of any litigation or other legal proceedings are uncertain, the Company is not currently a party to any material legal proceedings that, if determined adversely to the Company, would individually or taken together have a material adverse effect on the Company’s business, financial position, results of operations or cash flows. The Company accrues loss contingencies when it is both probable that a loss will be incurred and when the amount of the loss or range of loss can be reasonably estimated.

​

Indemnification Provisions

​

The Company’s agreements include provisions indemnifying customers against intellectual property and other third-party claims. In addition, the Company has entered into indemnification agreements with its directors, executive officers and certain other officers that require the Company, among other things, to indemnify them against certain liabilities that may arise as a result of their affiliation with the Company. The Company has not incurred any costs as a result of such indemnification obligations and has not recorded any liabilities related to such obligations in the condensed consolidated financial statements.

​

26

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management’s Discussion and Analysis of Financial Condition and Results of Operations section should be read in conjunction with the condensed consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q. This discussion and analysis contains forward-looking statements, such as statements of our plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect,” “will,” “continue,” “project,” “forecast,” “goal,” “should,” “could,” “would,” “potential,” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including those described under Part I “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, as updated under Part II “Item 1A. Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. See “Cautionary Note Regarding Forward-Looking Statements” elsewhere in this Quarterly Report on Form 10-Q.

​

For purposes of this discussion, “Rigetti,” “the Company,” “we,” “us” or “our” refer to Rigetti Computing, Inc. and its subsidiaries unless the context otherwise requires.

​

Overview

​

We build quantum computers and the superconducting quantum processors that power them. We believe quantum computing represents one of the most transformative emerging capabilities in the world today. By leveraging quantum mechanics, we believe our quantum computers process information in fundamentally new, more powerful ways than classical computers. When scaled, it is anticipated that these systems will be poised to solve problems of staggering computational complexity at unprecedented speed.

​

With the goal of unlocking this opportunity, we have developed the world’s first multi-chip quantum processor for scalable quantum computing systems. We believe that this patented and patent pending, modular chip architecture is the building block for new generations of quantum processors that we expect to achieve a clear advantage over classical computers. Our long-term business model centers on revenue generated from sales of quantum processing units (QPUs) and quantum computing systems made accessible via the cloud in the form of Quantum Computing as a Service (“QCaaS”) products. However, the substantial majority of our revenues are currently derived from development contracts, and we anticipate this market opportunity will continue to represent an important source of revenue for at least the next several years as we work to ramp up sales of QPUs and our QCaaS business. Additionally, we are working to further develop a revenue stream and forging important customer relationships by entering into technology development contracts with various partners.

​

We are a vertically integrated company. We operate Fab-1, a wafer fabrication facility dedicated to prototyping and producing our quantum processors. Through Fab-1, we own the means of production of our breakthrough multi-chip quantum processor technology. We leverage our chips through a full-stack product development approach, from quantum chip design and manufacturing through cloud delivery. We believe this full-stack development approach offers both the fastest and lowest risk path to building commercially valuable quantum computers. We have been generating revenue since 2018 through partnerships with government agencies and commercial organizations; however, we have incurred significant operating losses since inception. Our net losses were $201.0 million and $75.1 million for the years ended December 31, 2024 and December 31, 2023, respectively. We incurred an operating loss for the three months ended June 30, 2025. We expect to continue to incur additional losses for the foreseeable future as we invest in research, development, and infrastructure consistent with our long-term business strategy. As of June 30, 2025, we had an accumulated deficit of $551.8 million.

​

Based on our forecasts, we believe that our existing cash, cash equivalents and available for sale investments should be sufficient to meet our anticipated operating cash needs for at least the next 12 months based on our current business plan, and expectations and assumptions considering current macroeconomic conditions. Our operating plans may change because of factors currently unknown, and we may need to seek additional funds sooner than planned, through public or private equity or debt financing or other sources, such as strategic collaborations or other transactions. In addition, we may seek additional capital even if we believe that we have sufficient funds for current or future operating plans.

​

In the fourth quarter of 2024, we announced the launch of our 84-qubit Ankaa-3 system, our newest flagship quantum computer featuring an extensive hardware redesign. We also achieved major two-qubit gate fidelity milestones with Ankaa-3: successfully halving error rates in 2024 to achieve a 99.0% median two-qubit iSWAP gate fidelity, as well as demonstrating a 99.5% median two-qubit fidelity with fSim gates. For more information on iSWAP gate fidelity and fSIM gates, see the section entitled “Our Technology—Our Superconducting Quantum Processors—Fidelity” in Part I, Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2024.

27

Table of Contents

Our goal for 2025 is to introduce the next generation of our modular system architecture, while continuing to increase fidelities. On July 16, 2025, we announced that we achieved our mid-year performance milestone of 99.5% median two-qubit gate fidelity on a modular 36-qubit system, a 2x reduction in median two-qubit gate error rate from our previous best results on our 84-qubit single chip Ankaa™-3 system. Composed of four 9-qubit chips (“chiplets”) tiled together and optimized for CZ gates, a commonly used two-qubit gate for executing quantum circuits with equivalent computational power to iSWAP gates, the 36-qubit system is based on our proprietary modular chip technology and provides a path to building a 100+ qubit chiplet-based system. Our 36-qubit system, Cepheus™-1-36Q, has been released for general availability and deployed on our Cloud Services Platform (QCS®) and will be available on Microsoft Azure thereafter. We expect to release a 100+ qubit chiplet-based system with a 99.5% median two-qubit gate fidelity before the end of 2025.

​

We believe that we will be able to achieve our plans for 2025 described above and elsewhere in this Quarterly Report on Form 10-Q; however, we face various risks and uncertainties relating to our business that could cause actual results to differ materially from our expectations stated herein. This Quarterly Report on Form 10-Q, including this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the section entitled “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, as updated under Part II “Item 1A. Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q.

​

2025 ATM Offering

​

On May 29, 2025, we entered into an Open Market Sale AgreementTM (the “Sales Agreement”) with Jefferies LLC with respect to an At-the-Market (“ATM”) offering program, pursuant to which we sold, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of $350 million. The shares offered and sold in the ATM offering were issued pursuant to a shelf registration statement on Form S-3 and the related prospectus supplement. During the three and six months ended June 30, 2025, we raised gross proceeds of $350 million from the sale of 30,309,780 shares of our common stock pursuant to the Sales Agreement, at a weighted average price of $11.55 per share. The net proceeds from the Sales Agreement during the three and six months ended June 30, 2025 were $346.7 million. As of June 30, 2025, there were no remaining shares available for sale pursuant to the Sales Agreement.

​

Quanta Collaboration Agreement

​

In February 2025, our wholly-owned subsidiary entered into a Collaboration Agreement with Quanta, whereby the parties may enter into written statements of work from time to time pursuant to which Quanta will develop Covered Components listed in such statement of work that meet our specifications and requirements. “Covered Components” may include control systems, dilution refrigerators, flexible cables, and select other non-QPU components suitable for our quantum computing products. No statements of work were entered into by the parties in connection with the entry into the Collaboration Agreement. In addition, the parties have each agreed to invest at least $250 million over the next five years in the field of quantum computing (and Quanta’s investment will be towards personnel and capital expenditures for developing products and services and manufacturing capability in furtherance of our product roadmap). No equity or joint venture was formed under the Collaboration Agreement and costs incurred by us under the Collaboration Agreement, consisting of expenditures for research and development and related capital, will be accounted for in accordance with GAAP as incurred.

​

Under the Collaboration Agreement, we will retain all rights, title and ownership to all QPU Technology (as defined in the Collaboration Agreement) and related intellectual property (“IP”) rights created in the course of activities specified in a statement of work under the Collaboration Agreement. Other than the QPU Technology and IP rights described above, to the extent there is any jointly created, invented or other developed technology in the course of the performance of activities specified in a statement of work under the Collaboration Agreement, the Company and Quanta will jointly own, and each party will hold a one-half undivided interest in, all such joint project technology and all newly-created or newly-arising IP rights with respect thereto.

​

In connection with the Collaboration Agreement, on February 27, 2025, we entered into a Securities Purchase Agreement with Quanta, pursuant to which we agreed to sell and issue to Quanta in a private placement transaction 3,020,412 shares of our Common Stock at a price per share of approximately $11.59, for an aggregate value of approximately $35.0 million. The private placement transaction, which was subject to regulatory clearance, closed on April 29, 2025.

​

Macroeconomic Considerations

​

Results of our operations have varied and may continue to vary based on the impact of changes in the domestic or global economy. Negative conditions in the general economy both in the United States and abroad, including conditions resulting from changes in gross domestic product growth, inflation, interest rates, financial and credit market fluctuations, supply chain constraints, international trade policies including tariffs and export controls, national security interests, pandemics, political turmoil, natural catastrophes, warfare, and terrorist attacks in the United States or elsewhere, could negatively affect our business, including progress toward the development of quantum computing by increasing the cost of materials and components and our operating costs.

28

Table of Contents

It is not possible at this time to estimate the long-term impact that these and related events could have on our business, as the impact will depend on future developments, which are highly uncertain and cannot be predicted. If these conditions persist and deepen, we could experience an inability to access additional capital if needed, or our liquidity could otherwise be impacted, and the trading price of our Common Stock could decline.

​

For further discussion of the potential impacts of macroeconomic events on our business, financial condition, and operating results, see the section titled Part I “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, including the risk factor titled “Unfavorable conditions in our industry or the global economy could limit our ability to grow our business and negatively affect our results of operations.”

​

Key Components of Results of Operations

​

Revenue

​

We generate revenue through our development contracts, as well as from our sales of QPUs, and our QCaaS offerings and other services including training and provision of quantum computing components. Development contracts are generally multi-year, non-recurring arrangements pursuant to which we provide professional services regarding collaborative research in practical applications of quantum computing to technology and business problems within the customer’s industry or organization and assists the customer in developing quantum algorithms and applications to assist customers in areas of business interest.

​

Cost of Revenue

​

Cost of revenue consists primarily of all direct and indirect costs associated with sales of QPUs, QCaaS offerings and development contracts and other services, including materials, employee costs for program management and personnel associated with the delivery of goods and services to customers, and sub-contract costs for work performed by third parties. Cost of revenue also includes an allocation of facility costs, depreciation and amortization directly related to the development contracts and QCaaS offerings and other services.

​

Operating Expenses

​

Our operating expenses primarily consist of research and development, and selling, general and administrative expenses.

​

Research and Development

​

Research and development expenses include compensation, employee benefits, stock-based compensation, outside consultant fees, facility costs, depreciation and amortization, materials and components purchased for research and development. We expect research and development expenses to increase as we continue to invest in quantum computing and the superconducting quantum processors needed for quantum computers. We do not currently capitalize any research and development expenditures. Research and development costs are expensed as incurred.

​

Selling, General and Administrative

​

Selling, general and administrative expenses include compensation, employee benefits, stock-based compensation, insurance, facility costs, professional service fees, and other general overhead costs other than those associated with research and development or sales of QPUs and providing development contracts, QCaaS offerings and other services. We expect selling, general and administrative expenses to increase as we grow our business, particularly to the extent we are able to demonstrate the usefulness of quantum computers and achieve broad quantum advantage, and subsequently enhance our product and service offerings, expand our customer base, and implement new marketing strategies.

​

Provision for Income Taxes

​

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized. We have recorded a full valuation allowance against our deferred tax assets.

​

29

Table of Contents

Results of Operations

​

Comparison of the Three and Six Months Ended June 30, 2025 and June 30, 2024

​

The following table sets forth our results of operations for the periods indicated (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Six months ended | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | 2025 versus 2024 | ​ | ​ | June 30, | ​ | 2025 vs. 2024 | ​ | ​
​ |  | 2025 | ​ | 2024 | ​ | $ Change | ​ | % Change | ​ | ​ | 2025 | ​ | 2024 | ​ | $ Change | ​ | % Change | ​ | ​
Revenue |  | $ | 1,801 |  | $ | 3,086 |  | $ | (1,285) |  | (42) | % |  | $ | 3,273 |  | $ | 6,138 |  | $ | (2,865) |  | (47) | % | ​
Cost of revenue | ​ |  | 1,235 | ​ |  | 1,096 | ​ |  | 139 |  | 13 | % | ​ |  | 2,265 | ​ |  | 2,648 | ​ |  | (383) |  | (14) | % | ​
Total gross profit | ​ |  | 566 | ​ |  | 1,990 | ​ |  | (1,424) |  | (72) | % | ​ |  | 1,008 | ​ |  | 3,490 | ​ |  | (2,482) |  | (71) | % | ​
Operating expenses: | ​ |  |  | ​ |  |  | ​ |  |  |  |  | ​ | ​ |  |  | ​ |  |  | ​ |  |  |  |  | ​ | ​
Research and development | ​ |  | 13,522 | ​ |  | 11,870 | ​ |  | 1,652 |  | 14 | % | ​ |  | 28,977 | ​ |  | 23,341 | ​ |  | 5,636 |  | 24 | % | ​
Selling, general and administrative | ​ |  | 6,926 | ​ |  | 6,205 | ​ |  | 721 |  | 12 | % | ​ |  | 13,545 | ​ |  | 12,819 | ​ |  | 726 |  | 6 | % | ​
Total operating expenses | ​ |  | 20,448 | ​ |  | 18,075 | ​ |  | 2,373 |  | 13 | % | ​ |  | 42,522 | ​ |  | 36,160 | ​ |  | 6,362 |  | 18 | % | ​
Loss from operations | ​ |  | (19,882) | ​ |  | (16,085) | ​ |  | (3,797) |  | 24 | % | ​ |  | (41,514) | ​ |  | (32,670) | ​ |  | (8,844) |  | 27 | % | ​
Other income (expense), net | ​ |  |  | ​ |  |  | ​ |  |  |  |  | ​ | ​ |  |  | ​ |  |  | ​ |  |  |  |  | ​ | ​
Interest expense | ​ | ​ | — | ​ | ​ | (969) | ​ | ​ | 969 |  | (100) | % | ​ | ​ | — | ​ | ​ | (2,076) | ​ | ​ | 2,076 |  | (100) | % | ​
Interest income | ​ |  | 3,042 | ​ |  | 1,218 | ​ |  | 1,824 |  | 150 | % | ​ | ​ | 5,194 | ​ |  | 2,341 | ​ |  | 2,853 |  | 122 | % | ​
Change in fair value of derivative warrant liabilities | ​ |  | (20,557) | ​ |  | 2,100 | ​ |  | (22,657) |  | NM | ​ | ​ | ​ | 32,705 | ​ |  | (483) | ​ |  | 33,188 |  | NM | ​ | ​
Change in fair value of earn-out liabilities | ​ |  | (2,257) | ​ |  | 1,315 | ​ |  | (3,572) |  | (272) | % | ​ | ​ | 6,580 | ​ |  | (306) | ​ |  | 6,886 |  | NM | ​ | ​
Total other income (expense), net | ​ |  | (19,772) | ​ |  | 3,664 | ​ |  | (23,436) |  | (640) | % | ​ |  | 44,479 | ​ |  | (524) | ​ |  | 45,003 |  | NM | ​ | ​
Net income (loss) before provision for income taxes | ​ |  | (39,654) | ​ |  | (12,421) | ​ |  | (27,233) |  | 219 | % | ​ |  | 2,965 | ​ |  | (33,194) | ​ |  | 36,159 |  | (109) | % | ​
Provision for income taxes | ​ |  | — | ​ |  | — | ​ |  | — |  |  | ​ | ​ |  | — | ​ |  | — | ​ |  | — |  |  | ​ | ​
Net income (loss) | ​ | $ | (39,654) | ​ | $ | (12,421) | ​ | $ | (27,233) |  |  | ​ | ​ | $ | 2,965 | ​ | $ | (33,194) | ​ | $ | 36,159 |  |  | ​ | ​

*NM – Not Meaningful

​

Revenue

​

Revenue decreased by $1.3 million and $2.9 million for the three and six months ended June 30, 2025, when compared to the three and six months ended June 30, 2024, respectively. The decreases were mainly due to reductions in revenue from collaborative research and professional services contracts. Our revenue has been negatively impacted by expiration of the National Quantum Initiative Act in September 2023 and its pending reauthorization in the United States Congress.

​

Our development contracts are typically fixed price milestone or cost share-based contracts and the timing and amounts of revenue recognized in any given period will vary significantly based on the delivery of the associated milestones and/or the work performed. The timing and delivery of sales of QPUs and QCaaS will also vary and impact revenue in any given quarterly or annual period. Revenue is expected to vary in terms of timing and size, resulting in significant fluctuations in revenue levels in future periods.

​

For the next few years, we expect much of our revenue to be generated from development contracts and anticipated sales of on-premises QPUs.

​

Cost of Revenue

​

Cost of revenue increased by $0.1 million and decreased by $0.4 million for the three and six months ended June 30, 2025, when compared to the three and six months ended June 30, 2024, respectively. The increase in cost of revenue during the three months ended June 30, 2025 was due to an unfavorable revenue mix, with more revenue and cost of revenue coming from contracts with higher costs and a lower gross margin profile, mostly offset by the impact of lower revenue levels on cost of revenue. The decrease in cost of revenue for the six months ended June 30, 2025 was due to the impact of lower revenue levels on cost of revenue, offset in part by the unfavorable revenue mix.

​

Our cost of revenue and gross margins are impacted by the composition of our revenue and variability in the pricing and terms of our development contracts. During the three and six months ended June 30, 2025, we recognized revenue and cost of revenue from contracts to deliver 24-qubit and 36-qubit quantum computing systems, which have higher costs and a lower gross margin profile than most of our other contracts.

​

We expect that cost of revenue and total gross profit as a percentage of revenue will vary in future quarterly and annual periods due to changes in the composition of our revenue and variability in the pricing and terms of our development contracts.

30

Table of Contents

Operating Expenses

​

Research and Development

​

Research and development expenses increased by $1.7 million and $5.6 million for the three and six months ended June 30, 2025, when compared to the three and six months ended June 30, 2024, respectively.

​

The increase in research and development expenses for the three months ended June 30, 2025, when compared to the three months ended June 30, 2024, was mainly due to a $1.2 million increase in salaries and employee related costs and a $0.5 million increase in consulting services. The increase in research and development expenses for the six months ended June 30, 2025, when compared to the six months ended June 30, 2024, was mainly due to a $3.2 million increase in salaries and employee related costs, a $1.1 million increase in stock based compensation, a $0.9 million increase in consulting services and a $0.4 million increase in all other costs. The increase in salaries and employee related costs in both periods was due to annual salary increases, new hires and higher Federal Insurance Contributions Act (“FICA”) taxes related to the vesting of RSUs and the increase in our stock price. The increase in stock-based compensation for the six months ended June 30, 2025 was mainly due to the grant of RSUs for employee spot bonuses. Consulting services are used to support information technology requirements and for non-core research and development activities.

​

We anticipate that research and development expenditures will grow in the future as we continue to focus on our technology roadmap and long-term goal of achieving broad quantum advantage.

​

Selling, General and Administrative

​

Selling, general and administrative expenses increased by $0.7 million for both the three and six months ended June 30, 2025, when compared to the three and six months ended June 30, 2024, respectively. The increase for both periods was mainly due to higher costs for proxy distribution and solicitation related to our annual meeting during the three months ended June 30, 2025, as compared to costs related to our annual meeting during the three months ended June 30, 2024, which was driven by the increase in the number of beneficial owners of our common stock.

​

We expect to incur additional selling, general and administrative expenses to support the growth of our business. Further, we expect selling, general and administrative expenses to increase over the longer term, particularly after we potentially achieve quantum advantage, and plan to subsequently enhance our sales and service offerings, expand our customer base, and implement new marketing strategies.

​

Other income and (expense), net

​

Interest expense

​

Interest expenses decreased by $1.0 million and $2.1 million for the three and six months ended June 30, 2025, when compared to the three and six months ended June 30, 2024, respectively. The reduction in interest expense was due to the prepayment of our outstanding debt with Trinity Capital Inc. (“Trinity Capital”) in December 2024. A discussion regarding the debt prepayment is included in Note 6 to our condensed consolidated financial statements for the three and six months ended June 30, 2025, included elsewhere in this Quarterly Report on Form 10-Q.

​

Interest income

​

Interest income was $3.0 million and $5.2 million for the three and six months ended June 30, 2025, respectively, compared to $1.2 million and $2.3 million for the three and six months ended June 30, 2024, respectively. The increase in interest income during the three and six months ended June, 2025, when compared to the three and six months ended June 30, 2024, was due to an increase in the balances of our invested cash and available-for-sale investments resulting from our equity offerings during late 2024 and the three months ended June 30, 2025. Fluctuations in the rates of interest earned on our investments also had an impact on interest income during these periods. We anticipate that interest income will increase in the coming periods due to the increase in the balances of our invested cash and available-for-sale investments resulting from the closing of our private placement with Quanta and our ATM offering during the three months ended June 30, 2025.

​

Change in Fair Value of Warrant Liabilities

​

A discussion of the change in the fair value of the warrant liabilities is included in Note 7 to our condensed consolidated financial statements for the three and six months ended June 30, 2025, included elsewhere in this Quarterly Report on Form 10-Q.

​

31

Table of Contents

The change in fair value of our warrant liabilities for the three and six months ended June 30, 2025 was a loss of $20.6 million and gain of $32.7 million, respectively. The change in fair value of our warrant liabilities for the three and six months ended June 30, 2024 was a gain of $2.1 million and a loss $0.5 million, respectively. The change in fair value for the three and six months ended June 30, 2025 was primarily due to fluctuations in our stock price.

​

Change in Fair Value of Earn-Out Liabilities

​

A discussion of the change in the fair value of the earn-out liabilities is included in Note 8 to our condensed consolidated financial statements for the three and six months ended June 30, 2025, included elsewhere in this Quarterly Report on Form 10-Q.

​

The change in fair value of our earn-out liabilities for the three and six months ended June 30, 2025 was a loss of $2.3 million and gain of $6.6 million, respectively. The change in fair value of our earn-out liabilities for three and six months ended June 30, 2024 was a gain of $1.3 million and a loss of $0.3 million, respectively. The change in fair value for the three and six months ended June 30, 2025 was primarily due to fluctuations in our stock price.

​

Provision for Income Taxes

​

We have incurred a cumulative pre-tax loss for the past three years. We expect to continue to incur losses for income tax purposes for the foreseeable future, and will continue to carry a full valuation allowance for our deferred tax assets. Accordingly, we did not record a provision for income taxes for either the three and six months ended June 30, 2025 or the three and six months ended June 30, 2024.

​

On July 4, 2025, new federal tax and budget legislation, known as the “One Big Beautiful Bill Act” (“OBBA”) was signed into law. Any financial impacts from the legislation will be reflected in our condensed consolidated financial statements during the three months ended September 30, 2025 when the legislation became law. We presently do not expect the OBBA to have a material impact on the condensed consolidated financial statements.

​

Liquidity and Capital Resources

​

We have incurred net losses and negative cash flows since inception. Historically, we financed our operations primarily through the sale and issuance of Common Stock, preferred stock, warrants, convertible notes, debt and revenues. During the years ended December 31, 2024 and December 31, 2023, we incurred net losses of $201.0 million and $75.1 million, respectively. As of June 30, 2025, we had an accumulated deficit of $551.8 million, and we expect to incur additional losses for the foreseeable future.

​

We believe that our existing balances of cash, cash equivalents and available-for-sale investments should be sufficient to meet our anticipated operating cash needs for the next 12 months based on our current business plan, and expectations and assumptions considering current macroeconomic conditions. Our operating plan may change because of factors currently unknown, including factors described herein, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations or other transactions. In addition, we may seek additional capital even if we believe that we have sufficient funds for current or future operating plans.

​

We have based these estimates on assumptions that may prove to be wrong and we could use our available capital resources sooner than we currently expect, and future capital requirements and the adequacy of available funds will depend on many factors including those described in the section titled “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, as updated under Part II “Item 1A. Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q.

​

If we are unable to raise capital when needed and on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs and/or other efforts. A recession or market corrections resulting from the impact of macroeconomic conditions could materially affect our business and the value of our securities.

​

Our cash requirements include employee-related costs such as salaries and benefits; materials and components for research and development; working capital requirements; capital expenditures for our quantum chip fabrication facility; quantum computing refrigerators and other requirements; planned development of multiple generations of quantum processors; anticipated investments to scale our operations in the future; and strategic collaborative arrangements and investments.

​

With respect to our longer-term future cash requirements, we will require a significant amount of cash for expenditure as we invest in ongoing research and development and business operations, including with respect to the Collaboration Agreement with Quanta, pursuant to which we are required to invest at least $250.0 million in the field of quantum computing in furtherance of our product roadmap over a five year period commencing on February 27, 2025.

​

32

Table of Contents

Until such time as we can generate significant revenue from sales of QPUs, our development contracts and other services, including our QCaaS offering, we believe we will meet our cash requirements and obligations primarily through our existing cash, cash equivalents and available-for-sale investments, potential securities financings or other capital sources. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be, or could be, diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders.

.

Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds through equity or debt financings when needed and on attractive terms, we may be required to delay, limit, or substantially reduce our quantum computing development efforts. Our future capital requirements and the adequacy of available funds will depend on many factors, including those described in the section under Part I “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, as updated under Part II “Item 1A. Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q.

​

Macroeconomic conditions, including inflation, interest rates and impacts from government policy and actions, such as international trade restrictions and policies and tariffs, may have adverse consequences, which may result in an economic recession globally or in the U.S., which could lead to a reduction in product demand, a decrease in corporate capital expenditures, prolonged unemployment, labors shortages, reduction in consumer confidence, adverse geopolitical and macroeconomic events, or any similar negative economic condition. In addition, macroeconomic and geopolitical conditions may lead to disruptions to, and volatility and uncertainty in, the credit and financial markets in the U.S. and worldwide.

​

Cash Flows Used in Operating Activities

​

Our cash flows from operating activities are significantly affected by our ability to achieve significant growth to offset expenditures related to research and development, and selling, general and administrative activities. Our operating cash flows are also affected by our working capital needs to support growth in personnel-related expenditures and fluctuations in accounts payable and other current assets and liabilities.

​

Net cash used in operating activities during the six months ended June 30, 2025 was $29.8 million, primarily resulting from our net income of $3.0 million, reduced by non-cash income totaling $30.5 million. Changes in operating assets and liabilities had a $2.3 million negative impact on net cash used in operating activities during six months ended June 30, 2025.

​

Net cash used in operating activities during the six months ended June 30, 2024 was $26.7 million, primarily resulting from our net loss of $33.2 million, partially offset by non-cash expenses totaling $10.0 million. Changes in operating assets and liabilities had a $3.4 million negative impact on net cash used in operating activities during the six months ended June 30, 2024.

​

Cash used in operating activities increased by $3.1 million to $29.8 million during the six months ended June 30, 2025, from $26.7 million during the six months ended June 30, 2024. We recorded net income of $3.0 million for the six months ended June 30, 2025, a $36.2 million improvement when compared to the net loss for the six months ended June 30, 2024, mostly due to non-cash changes in the fair value of derivative warrant and earn-out liabilities. Non-cash income impacting our net income increased by $40.5 million to $30.5 million during the six months ended June 30, 2025, when compared to non-cash expenses of $10.0 million during the six months ended June 30, 2024. Operating assets and liabilities had a $1.1 million favorable impact on the change in cash used in operating activities for the six months ended June 30, 2025, when compared to the six months ended June 30, 2024.

​

Cash Flows Used in Investing Activities

​

Cash used in investing activities during the six months ended June 30, 2025 totaled $369.7 million, resulting from $438.5 million of purchases of available-for-sale securities and $8.2 million of purchases of property and equipment, partially offset by $77.0 million of maturities of available-for-sale securities.

​

Cash used in investing activities during the six months ended June 30, 2024 totaled $7.0 million, resulting from $76.0 million of purchases of available-for-sale securities and $7.5 million of purchases of property and equipment, offset in part by $76.5 million of maturities of available-for-sale securities.

​

Investments in property and equipment relate primarily to process computing equipment, quantum computing refrigerators, and development tools for our chip fabrication facility.

​

Net cash used in investing activities during the six months ended June 30, 2025 increased by $362.7 million, when compared to the six months ended June 30, 2024, primarily due to investment of the proceeds from our recent $350.0 million ATM offering, resulting in an increase in purchases of available-for-sale securities.

33

Table of Contents

Cash Flows Provided by Financing Activities

​

Cash provided by financing activities during the six months ended June 30, 2025 totaled $389.1 million. We received net proceeds of $346.7 million from the sale of 30,309,780 shares of common stock pursuant to our ATM program that was completed in the six months ended June 30, 2025. We received proceeds of $35.0 million from the sale of 3,020,412 shares of common stock from the private placement transaction with Quanta. We received proceeds of $6.3 million from tax withholdings on sell-to-cover tax equity award transactions, proceeds of $1.4 million from the exercise of stock options and proceeds of $0.5 million from the exercise of warrants. We also paid $0.8 million for offering costs.

​

Cash provided by financing activities during the six months ended June 30, 2024 totaled $33.1 million. We received net proceeds of $12.8 million from the sale of 10,056,799 shares of common stock to B. Riley through our prior Purchase Agreement and net proceeds of $26.8 million from the sale of 19,423,375 shares of common stock pursuant to our prior ATM program. Proceeds from the sale of common stock were offset in part by principal payments of $6.2 million under the amended loan agreement with Trinity Capital and payments of $0.4 million for deferred offering costs

​

Cash provided by financing activities increased by $356.0 million during the six months ended June 30, 2025, when compared to the six months ended June 30, 2024. The increase was primarily due to the $346.7 million of net proceeds we received from our $350.0 million ATM offering completed in June 2025. Other factors favorably impacting the increase in cash provided by financing activities during the six months ended June 30, 2025, when compared to the six months ended June 30, 2024, include proceeds of $35.0 million from the sale of common stock to Quanta, $6.3 million from tax withholdings on sell-to-cover tax equity award transactions and a $6.2 million reduction in payments of principal of notes payable due to the prepayment of our outstanding debt with Trinity Capital in December 2024. These increases were offset in part by proceeds of $39.7 million from sales of common stock during the six months ended June 30, 2024.

​

Contractual Obligations and Contingencies

​

See Note 16 to our unaudited interim condensed consolidated financial statements located in “Part I – Financial Information, Item 1. Notes to Condensed Consolidated Financial Statements” in this Quarterly Report for a description of our contractual obligations and contingencies.

​

Critical Accounting Policies and Significant Judgements and Estimates

​

This discussion and analysis of financial condition and results of operations is based upon the Company’s condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities. We also make estimates and assumptions pertaining to revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances. The results of these estimates form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

​

There have been no material changes to our critical accounting estimates from those described under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2024.

​

Critical accounting estimates are defined as those reflective of significant judgments, estimates and uncertainties, which may result in materially different results under different assumptions and conditions. Within our Annual Report on Form 10-K for the year ended December 31, 2024, we have disclosed our critical accounting estimates that we believe have the greatest potential impact on our consolidated financial statements. Historically, our assumptions, judgments and estimates relative to our critical accounting estimates have not differed materially from actual results.

​

Recently Issued Accounting Pronouncements

​

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 of our condensed consolidated financial statements for the three and six month periods ended June 30, 2025 included elsewhere in this Quarterly Report on Form 10-Q.

​

34

Table of Contents

Emerging Growth Company and Smaller Reporting Company Status

​

In April 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” (“EGC”) may take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Therefore, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Following the Business Combination, we still qualify as an emerging growth company and plan to take advantage of the extended transition period that emerging growth company status permits. During the extended transition period, it may be difficult or impossible to compare our financial results with the financial results of another public company that complies with public company effective dates for accounting standard updates because of the potential differences in accounting standards used.

​

We will remain an EGC under the JOBS Act until the earliest of (a) December 31, 2026, (b) the last date of our fiscal year in which we have total annual gross revenue of at least $1.235 billion, (c) the date on which we are deemed to be a “large accelerated filer” under the rules of the SEC or (d) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the previous three years.

We are also a “smaller reporting company” as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an EGC. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as the market value of our voting and non-voting Common Stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our voting and non-voting Common Stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.

On June 30, 2025, the last business day of our second fiscal quarter in 2025, the aggregate market value of our voting and non-voting common equity held by non-affiliates exceeded $700.0 million. Accordingly, we will be deemed to be a “large accelerated filer” under the rules of the SEC as of December 31, 2025. As such, we will no longer (i) qualify as an EGC under the rules of the SEC, (ii) be eligible to take advantage of the extended transition period for the adoption of new or revised accounting pronouncements available to an EGC beginning with our Annual Report on Form 10-K for the fiscal year ending December 31, 2025 and (iii) be exempt from providing an auditor’s attestation report on internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act. In addition, under the current rules of the SEC, we will no longer be eligible to take advantage of the scaled disclosures available to smaller reporting companies beginning with our Quarterly Report on Form 10-Q for the first quarter of 2026.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule12b-2 of the Exchange Act and are not required to provide the information required under this item.

​

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

​

We maintain “disclosure controls and procedures,” as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

​

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2025. Based on the evaluation of our disclosure controls and procedures, our principal executive officer and principal financial officer concluded that, as of June 30, 2025, our disclosure controls and procedures were effective at a reasonable assurance level.

​

Changes in Internal Control over Financial Reporting

​

There were no material changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

​

35

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may be subject to litigation and claims arising in the ordinary course of business. While the results of any litigation or other legal proceedings are uncertain, we are not currently a party to any material legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, financial position, results of operations or cash flows. We accrue for loss contingencies when it is both probable that we will incur the loss and when we can reasonably estimate the amount of the loss or range of loss.

​

ITEM 1A. RISK FACTORS

​

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K Risk Factors”) for a more complete understanding of the risks and uncertainties material to our business that make an investment in our securities speculative or risky. There have been no material changes to our risk factors as previously disclosed in the 2024 Form 10-K Risk Factors, except as follows:

​

We will no longer qualify as an “emerging growth company” or a “smaller reporting company” after December 31, 2025, and, as a result, we will have to comply with increased disclosure and compliance requirements.

​

We are currently an “emerging growth company” (an “EGC”) as defined in the JOBS Act. However, because the market value of our common stock held by non-affiliates exceeded $700 million as of June 30, 2025, we will no longer qualify as an EGC, a “smaller reporting company” or a “non-accelerated filer” as of December 31, 2025 and will be a large accelerated filer beginning January 1, 2026 for future filings, in accordance with current SEC rules.

​

As a large accelerated filer, we will be subject to certain disclosure and compliance requirements that apply to other public companies but that did not previously apply to us due to our status as an EGC. These requirements include, but are not limited to:

​

| ● | the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002;

| ● | compliance with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements;

| ● | the requirement that we provide more detailed disclosures regarding executive compensation; and

| ● | the requirement that we hold a non-binding advisory vote on executive compensation and obtain stockholder approval of any golden parachute payments not previously approved.

​

We expect that the loss of EGC status and compliance with the additional requirements of being a large accelerated filer will increase our legal, accounting and financial compliance costs and costs associated with investor relations activities, and cause management and other personnel to divert attention from operational and other business matters to devote substantial time to public company reporting requirements. In addition, if we are not able to comply with changing requirements in a timely manner, or if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities, which would require additional financial and management resources.

​

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

​

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

​

ITEM 4. MINE SAFETY DISCLOSURES

None.

​

36

Table of Contents

ITEM 5. OTHER INFORMATION

During the quarter ended June 30, 2025, the officers and directors listed below adopted or terminated trading plans intended to satisfy the affirmative defense conditions of Rule 10b5-1 (c) under the Exchange Act.

​

On May 15, 2025, Thomas Iannotti, a member of our board of directors, adopted a trading plan that provides for the sale of up to 200,000 shares of our Common Stock, depending on the market prices of the securities. The plan is scheduled to terminate on August 13, 2026, subject to earlier termination upon the sale of all securities subject to the plan, or as otherwise provided in the plan.

​

On June 12, 2025, Gail Sandford, a member of our board of directors, adopted a trading plan that provides for (i) the sale of a maximum of 25,000 shares of our Common Stock on a per week basis until $900,000 in gross sales proceeds has been achieved, (ii) assuming completion of the sales set forth in (i), the sale of up to 62,000 shares of our Common Stock, depending on the market prices of the securities, and (iii) the sale of 60% of the dollar value of the shares of our Common Stock underlying 14,902 RSUs that are scheduled to vest no later than June 10, 2026. The plan is scheduled to terminate on September 10, 2026, subject to earlier termination upon the sale of all securities subject to the plan, or as otherwise provided in the plan.

​

​

37

Table of Contents

​

ITEM 6 – EXHIBITS

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Exhibit |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Number | ​ | Description | ​ | Form | ​ | File No. | ​ | Exhibit | ​ | Filing Date
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2.1+ | ​ | Agreement and Plan of Merger, dated as of October 6, 2021, by and among Supernova Partners Acquisition Company II, Ltd., Supernova Merger Sub, Inc., Supernova Romeo | ​ | 8-K | ​ | 001-40140 | ​ | 2.1 | ​ | October 6, 2021
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2.2 | ​ | First Amendment to Agreement and Plan of Merger, dated as of December 23, 2021, by and among Supernova Partners Acquisition Company II, Ltd., Supernova Merger Sub, Inc., Supernova Romeo Merger Sub, LLC and Rigetti Holdings, Inc. | ​ | 8-K | ​ | 001-40140 | ​ | 2.1 | ​ | December 23, 2021
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2.3 | ​ | Second Amendment to Agreement and Plan of Merger, dated as of January 10, 2022, by and among Supernova Partners Acquisition Company II, Ltd., Supernova Merger Sub, Inc., Supernova Romeo Merger Sub, LLC and Rigetti Holdings, Inc. | ​ | 8-K | ​ | 001-40140 | ​ | 2.1 | ​ | January 10, 2022
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
3.1 | ​ | Certificate of Incorporation of Rigetti Computing, Inc. | ​ | 8-K | ​ | 001-40140 | ​ | 3.1 | ​ | March 7, 2022
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
3.2 | ​ | Amended and Restated Bylaws of Rigetti Computing, Inc. | ​ | 8-K | ​ | 001-40140 | ​ | 3.2 | ​ | November 14, 2022
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
4.1 | ​ | Specimen Common Stock Certificate | ​ | 8-K | ​ | 001-40140 | ​ | 4.1 | ​ | March 7, 2022
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
4.2 | ​ | Specimen Warrant Certificate | ​ | 8-K | ​ | 001-40140 | ​ | 4.2 | ​ | March 7, 2022
​ 10.1 | ​ | ​ Open Market Sale AgreementSM, by and between Rigetti Computing, Inc., and Jefferies LLC dated May 29, 2025. | ​ | 8-K | ​ | 001-40140 | ​ | 1.1 | ​ | May 29, 2025
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
10.2 | ​ | Non-Employee Director Compensation Policy | ​ | 10-Q | ​ | 001-40140 | ​ | 10.3 | ​ | May 12, 2025
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
31.1* | ​ | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2022 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
31.2* | ​ | Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
32.1** | ​ | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
32.2** | ​ | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

38

Table of Contents

101.INS* | ​ | Inline XBRL Instance Document—the instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
101.SCH* | ​ | Inline XBRL Taxonomy Extension Schema Document | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
101.CAL* | ​ | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
101.DEF* | ​ | Inline XBRL Taxonomy Extension Definition Linkbase Document | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
101.LAB* | ​ | Inline XBRL Taxonomy Extension Label Linkbase Document | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
101.PRE* | ​ | Inline XBRL Taxonomy Extension Presentation Linkbase Document | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
104* | ​ | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

* | Filed herewith

** | Furnished herewith

​

​

39

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​ | ​
​ | RIGETTI COMPUTING, INC.
​ | ​
​ | /s/ Subodh Kulkarni
​ | By Subodh Kulkarni, President and Chief Executive Officer
​ | (Principal Executive Officer and Duly Authorized Officer)
​ | ​
​ | /s/ Jeffrey A. Bertelsen
​ | By Jeffrey A. Bertelsen, Chief Financial Officer
​ | (Principal Financial Officer, Principal Accounting Officer and Duly Authorized Officer)
​ | ​
Date: August 12, 2025 | ​

​

​

​

​

​

40